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1. Goals of study/abstract in English language 
 
The main objective of my diploma thesis was determining the role of S100A8 and 
S100A9 in the development and progression of inflammatory skin diseases, in particular 
psoriasis. Both proteins are highly upregulated in the skin of psoriasis patients as well 
as in the mouse model for psoriasis caused by inducible, epidermal deletion of the two 
AP-1 family members JunB and c-Jun (JunBΔep* c-JunΔep* or DKO* mice, (1)). Induction 
of S100A8 and S100A9 in mice is observed even before appearance of disease symp-
toms (1). Therefore, analysis of the psoriasis-like skin disease in JunBΔep* c-JunΔep* mice 
provides a powerful tool to study S100A8 and S100A9 function. Importantly, loss of 
S100A9 in the Jun/AP-1 psoriasis mouse model significantly reduces the severity of the 
inflammatory phenotype (H. Schönthaler, unpublished data).  
The two main cell types involved in development of skin inflammations are epidermal 
keratinocytes and a variety of immune cells. The skin of the Jun/AP-1 psoriasis mouse 
model displays notable epidermal thickening due to keratinocyte hyperproliferation as 
well as pronounced immune cell invasion in dermis and epidermis (1). To determine if 
this is due to the loss of JunB and c-Jun in a cell autonomous manner, we investigated 
apoptosis and proliferation of keratinocytes in DKO* mice in vivo and in vitro. The re-
sults were compared to JunBΔep* c-JunΔep* S100A9-/- (TKO*) mice to identify the effect of 
S100A9 loss. Furthermore, we performed a histological and molecular characterization 
of the skin of these mice and analyzed the composition of the cutaneous immune cell 
infiltrate of DKO* and TKO* mice at different stages of the disease. Cytokine production 
in the dermis and epidermis, systemic mouse serum levels as well as cytokine secretion 
by cultured keratinocytes of the Jun/AP-1 psoriasis mouse model and TKO* mice was 
determined. That was done to understand the role of S100A9 in the cross talk between 
keratinocytes and immune cells in the course of skin inflammation and in order to find 
S100A9-dependent mediators in this cellular network. 
Finally, we hypothesized S100A8 and S100A9 overexpression per se may provoke an 
inflammatory skin phenotype and analyzed mice carrying a switchable Tet-ON system-
controlled transgene for S100A8 and S100A9. Unfortunately, we observed no consis-
tent increase in S100A8 or S100A9 protein levels in the epidermis of mice using induc-
tion of the S100A8/A9 transgene by two different transactivator lines. 
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In summary, S100A9 appears to induce inflammatory, psoriasis disease-like symptoms 
in multiple ways. Skin architecture, angiogenesis and expression of key inflammatory 
genes are largely normalized upon loss of S100A9 in the Jun/AP-1 psoriasis mouse 
model. S100A9 deficiency of TKO* mice leads to a decrease of dermal and epidermal 
immune cell infiltration, reduced epidermal proliferation and lower inflammatory cytokine 
levels in mouse sera compared to DKO* mice. Although S100A8 and S100A9 are up-
regulated in keratinocytes in vitro upon JunB and c-Jun deletion (1), cell proliferation is 
not affected in a cell autonomous manner. S100A9 does not have a pronounced cell 
autonomous effect on inflammatory cytokine secretion of keratinocytes, since superna-
tant levels of cultured DKO* and TKO* keratinocytes are largely similar. Thus, S100A9 
appears to play a complex role in the cross talk of keratinocytes and immune cells and 
seems to have an inducing effect on psoriasis and inflammatory skin reactions. 
 
 
2. Introduction 
 
The skin is not only the largest organ of the human body and the major sensation facili-
tator, but also provides protection against dehydration, excessive temperature changes 
as well as physical and chemical stress. It represents the first line of defense to avoid 
entrance of possible harmful pathogens from the environment. This is achieved by an 
acidic pH, a competing surface microbiota and a physical barrier lining the organism (2). 
The outermost layer of the skin is the epidermis and consists of multiple layers of tightly 
packed keratinocytes (approximately 95% of the total epidermis), dispersed by Langer-
hans cells, Merkel cells as well as melanocytes in the basal layer. In order to maintain 
the integrity of the epidermis, keratinocytes proliferate at the basal membrane and un-
dergo a differentiation program affecting their morphology and cytoskeleton towards the 
exterior to form a sealed, roof-like surface. Round-shaped keratinocytes form a network 
of desmosomal cell-to-cell junctions and accumulate lipid- and structural protein-
containing intracellular bodies in the spinous layer. Granular keratinocytes release the 
content of these numerous granules, including Odland bodies as well as lamellar bodies 
and keratinosomes. Moreover, they initiate degradation of intracellular organelles and 
the nucleus, flatten out and undergo apoptosis. Depending on their state of differentia-
tion, keratinocytes express distinct types of structural proteins, like Loricrin, Filaggrin 
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and various keratin proteins. They assemble to disulfide-linked intermediate filaments 
and form the matrix of the outermost layer of the epidermis. The cornified envelope 
(stratum corneum) is further supported by large amounts of released lipids, desmo-
somes and a network of Involucrin molecules cross-linked to membrane proteins 
(Fig. 1A, (3) and (4)). 
The dermis is less densely populated by cells, but rather represents connective tissue 
and elastic collagen fibers produced by embedded fibroblasts. It contains hair follicles, 
sebaceous glands and sweat glands, which penetrate through the overlaying epidermis. 
Fig. 1 – Overview of skin architecture, epidermal differentiation and psoriasis histopathology. 
(A) Schematic view of the skin with focus on the epidermal layers, keratinocyte differentiation and 
marker expression (J. Guinea-Viniegra, modified). 
(B) Haematoxylin and Eosin (H&E)-stained histology of normal and psoriatic human skin showing 
hallmarks of psoriasis (modified form (6)). 
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Networks of nerves, blood and lymph vessels spread throughout the dermis and ensure 
mechanical stress response, nutrition and moisture supply of the skin. Several immune 
cell types are resident in the dermis, including macrophages, mast cells, dentritic cells 
and lymphocytes ((2) and (5)). Due to the dense dermal vasculature and signals origi-
nating from skin cells, large numbers of innate and adaptive immunocytes readily infil-
trate the dermis and epidermis during inflammatory skin diseases upon deregulation of 
skin homeostasis. 
About 2-3 percent of the worldwide population suffer from psoriasis, a very heterogene-
ous skin disorder of unclear origin. Psoriasis vulgaris is the most frequent variant 
(around 90%) and numerous patients develop additionally psoriatic arthritis and/or nail 
psoriasis. The autoimmune-related skin disease has a genetic component, since it is 
more common among relatives and at least 12 significantly associated chomosomal 
loci, psoriasis susceptibility regions (PSORS), have been identified. It is characterized 
by scaly, protuberant demarcated plaques of variable dimension as a cause of epider-
mal hyperplasia and altered keratinocyte differentiation (Fig. 1B, (6), (7) and (8)). Fur-
ther hallmarks of psoriasis are increased blood supply by an enlarged network of dilated 
blood vessels as well as chronic inflammation with pronounced local leukocyte infiltra-
tion in the skin and an elevation of various cytokines, locally and systemically. Cytokines 
and immune cells, primarily TNFα and T lymphocytes, are tackled by most psoriasis 
targeted-therapies in the clinics, e.g. Infliximab and Efalizumab, respectively ((6), (7) 
and (8)). However, there is no cure yet and the initial cause of psoriasis as well as the 
essential steps leading to disease progression remain to be defined. 
In this study we employed a mouse model for psoriasis, the Jun/AP-1 psoriasis mouse 
model (1). Activator protein 1 (AP-1) is a dimeric transcription factor complex integrating 
several physiological and pathological stimuli to regulate proliferation, differentiation, 
apoptosis and transformation. Bacterial or viral infections, growth factors, cytokines or 
oncogenic signals activate MAPK kinase signaling cascades including ERK, JNK and 
p38-kinases. These, in turn, induce Jun, Fos, activating transcription factor (ATF) and 
musculoaponeurotic fibrosarcoma (MAF) proteins, which form homo-and heterodimers  
((9) and (10)). Knock-out and gain-of-function studies of AP-1 family members mainly in 
mice, demonstrated their various roles in different organs. 
Constitutive mutation of JunB or c-Jun results in lethality (11), epidermal JunB loss 
(JunBΔep) leads to a multiorgan disease (12) and keratinocyte-restricted c-Jun defi- 
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Fig. 2 – Loss of S100A9 in the Jun/AP-1 psoriasis mouse model leads to largely reduced in-
flammatory symptoms (H. Schönthaler, unpublished observation). 
(A) Jun/AP-1 psoriasis mouse model (modified from (1)): Treatment of experimental mice to generate 
JunB
Δep*
 c-Jun
Δep*
 mice, the Jun/AP-1 psoriasis mouse model. Five consecutive intraperitoneal injec-
tions of 1mg Tamoxifen per day of eight-weeks old mice lead to K5 Cre-mediated deletion of floxed 
JunB and c-Jun alleles. Mice were sacrificed and analyzed two weeks after the last Tamoxifen injec-
tion. Macroscopic images and H&E-stained sections of JunB
f/f
 c-Jun
f/f
  and JunB
Δep*
 c-Jun
Δep*
 mouse 
ears show a psoriasis-like skin disorder. Quantitative PCR amplification of S100A8 and S100A9 
mRNA of mouse epidermis with normal appearance 24 hours after tamoxifen injection for 3 consecu-
tive days displays upregulation of these genes in the Jun/AP-1 psoriasis mouse model. 
(B) Overview of genotype and terminology of mice used in this study (H. Schönthaler). Control, 
S100A9-/-, DKO* and TKO* mice received treatment as described in (A). Macroscopic images of 
mouse ears two weeks after the last tamoxifen injection and microscopic images (magnification 10x) 
of H&E-stained mouse ear sections reveal reduced symptoms in TKO* mice compared to the pro-
nounced skin inflammation observed in DKO* mice. 
ciency (c-JunΔep) to open eyes at birth as well as reduced tumor formation (13). The 
constitutive genetic deletion of both genes in the epidermis (JunBΔep c-JunΔep) causes 
death around birth due to massive TNFα shedding, skin inflammation and cachexia 
(14). Interestingly, the inducible epidermal deletion of JunB and c-Jun in adult mice 
(JunBΔep* c-JunΔep*) provokes a skin inflammatory disease highly reminiscent of human 
psoriasis (1). Eight week old mice carrying JunB and c-Jun floxed alleles as well as the 
keratin5-CreERT transgene and their littermate controls were injected with tamoxifen for 
five consecutive days to induce JunB and c-Jun gene deletion (Fig. 2A and (1)). Around 
two weeks after the last injection, mice showed pronounced skin scaling, increased epi-
dermal thickness, retention of nuclei in the cornified layer as well as rete ridges reaching 
into the dermis and augmented dermal angiogenesis with enlarged, permeable blood 
vessels (Fig. 2A, (1) and (15)). These histological changes appeared in accordance with 
a pronounced infiltration of innate immune cells into the dermis, presence of epidermal 
T lymphocytes and neutrophils and joint inflammation (1). The observed phenotype of 
JunBΔep* c-JunΔep* (DKO*) mice is highly similar to psoriasis (1), making it a very valid 
model to study the pathogenesis of psoriasis.  
On a molecular level, S100A8 and S100A9 protein expression is strongly elevated in 
the skin of the Jun/AP-1 psoriasis mouse model, even preceding disease symptoms 
(Fig. 2A and (1)). S100A8 and S100A9 are members of the S100 calcium-binding pro-
tein family, contain two EF-hand motifs and form a helix-loop-helix structure (16). They 
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seem to act as both, homo- and heterodimers in mice, while the human S100A8 and 
S100A9 proteins rather exist as heterodimers (known as Calprotectin) or oligomers (17). 
S100A8/A9 are remarkably abundant in myeloid cells and constitute 45% of solid pro-
teins in neutrophils and 1-2% in monocytes (18). They are also produced by other cell 
types, including activated macrophages (19) as well as fibroblasts (20) and their ex-
pression is induced in epithelial cells, including keratinocytes, upon infection or injury 
((21), (22) and (23)). 
Murine and human S100A8 and S100A9 appear to have manifold intracellular and 
extracellular functions. S100A8/A9 display strong chemotactic activity, especially at-
tracting neutrophils ((24), (25) and (26)), and have several anti-infective properties, e.g. 
they confer cellular resistance against adherence and invasion of microorganisms (27). 
S100A8/A9 have been described as damage-associated molecular patterns (DAMPs) 
secreted by phagocytes (28). They are implicated in migration of tumor cells as well as 
lung metastasis (29) and vasculature-derived S100A8/A9 influences leukocyte traffick-
ing (30). Additionally, S100A8 seems to be crucial for embryonic development, since its 
genetic deletion in mice leads to lethality at embryonic day E9.5 (31). In contrast, mice 
lacking S100A9 are viable, fertile and show absence of S100A8 protein ((32) and (33)). 
S100A9 deficiency did neither affect chemically induced peritonitis in mice nor myeloid 
cell functions in vitro, although S100A9-/- neutrophils are less dense and show a dose-
dependent reduction of chemotactic responses ((32), (33) and (34)). However, fewer 
granulocytes infiltrate wounded skin of S100A9 null mice due to transendothelial migra-
tion defects leading to improved wound healing (35) and the effects of shock and sepsis 
induction is reduced in mice lacking S100A9, because S100A8/A9 complexes appear to 
promote endotoxine-mediated inflammation (28). 
In humans, the S100A8 and S100A9 genes are located in the psoriasis susceptibility 
region PSORS4 (1p12) (36), their protein concentrations are profoundly elevated in pso-
riatic skin ((37) and (38)) and S100A8/A9 serum levels were associated with disease 
severity (39). Hence, S100A8 and S100A9 are considered to be potential mediators in 
skin inflammation and, in particular, psoriasis. 
We investigated the function of S100A8 and S100A9 proteins in skin inflammation and 
psoriasis using a gain of function and loss of function approach. Overexpression of 
S100A8 and S100A9 proteins in the skin of transgenic mice using the switchable 
Tet-ON system (S100A8/A9-rosa-tetON and S100A8/A9-k5-tetON mice, H. Schönthaler 
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in collaboration with P. Angel and colleagues) did, however, not result in an inflammato-
ry skin phenotype. In contrast, constitutive S100A9 gene deletion leads to tremendous 
improvement of psoriasis-like disease symptoms in the Jun/AP-1 psoriasis mouse mod-
el (H. Schönthaler). JunBΔep* c-JunΔep* S100A9-/- (TKO*) mice show less skin scaling, 
reduced epidermal thickening as well as a diminished inflammatory state of the skin in 
comparison to DKO* mice. S100A9 mutant mice (JunBf/f c-Junf/f S100A9-/-) in a steady 
state condition seem normal and histologically indistinguishable from littermate JunBf/f c-
Junf/f S100A9+/- controls (Fig. 2B, H. Schönthaler). 
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Fig. 3 – S100A9-deficiency causes overall normalization of skin architecture in the Jun/AP-1 
psoriasis mouse model. 
(A-D) Immunofluorescence for keratin 15 (K15, green channel) of ear sections of indicated mice. 
White arrows mark some K15-expressing cells in ears of control (A) and S100A9-/- (B) mice and cell 
nuclei were stained in blue by DAPI. Magnification is 20x, n=3 for control, S100A9-/- and DKO* mice 
and n=6 for TKO* mice. 
(E-P) Representative images of immunohistochemistry for keratin 5 (K5, E-H), keratin 10 (K10, I-L) 
and Loricrin (Lor, M-P) of control (n=3), S100A9-/- (n=3), DKO* (n=3) and TKO* (n=6) mice. Counters-
taining of cell nuclei was performed with haematoxylin (blue) and magnification is 10x. 
(Q-T) Quantitative PCR analysis of markers for keratinocyte differentiation of epidermis of mice with 
specified genotype (n=3, except for TKO* n=6). Data represent mean ± standard deviation and signifi-
cant alterations between groups were calculated using a student t-test and indicated as follows: (*) 
P<0.05, (**) P<0.01 and (***) P<0.001. Graphs show mRNA levels of the epidermal stem cell marker 
K15 (Q), the basal layer-expressed K5 and keratin 14 (K14) (R), markers of the spinous epidermal 
layer keratin 1 (K1) and K10 (S) and the granular layer-restricted Lor (T). 
Here, we determined the effect of S100A9 loss in the Jun/AP-1 psoriasis mouse model 
on keratinocyte differentiation, apoptosis as well as proliferation in vivo and in vitro and 
performed a histological and molecular analysis of the skin. We assessed cutaneous 
immune cell infiltration of DKO* and TKO* mice as well as systemic cytokine/chemokine 
levels in mouse sera and keratinocyte-conditioned medium to investigate the role of 
S100A9 proteins in skin inflammation and psoriasis.  
Furthermore, we analyzed endogenous S100A8 and S100A9 protein levels in several 
tissues and isolated keratinocytes of S100A8/A9-rosa-tetON and S100A8/A9-k5-tetON 
mice. Unfortunately, no consistent upregulation of S100A8 and S100A9 proteins was 
found in steady-state condition and upon inflammatory stimulus by TPA application. 
 
 
3. Results 
 
3.1. Analysis of skin morphology, cell proliferation and apoptosis in the skin of 
the Jun/AP-1 psoriasis mouse model upon loss of S100A9 
 
Pronounced cellular changes observed in human psoriatic skin are remarkably in-
creased thickness of the epidermis, altered skin architecture, hyperkeratosis and reten-
tion of nuclei in the stratum corneum. The skin of the Jun/AP-1 psoriasis mouse model 
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Fig. 4 – Hyperproliferation of psoriatic keratinocytes in DKO* is strongly reduced in TKO* mice. 
(A-L) Mouse ear sections were immunohistochemically stained for the keratinocyte-proliferation mark-
er keratin 6 (K6, A-D), the broad proliferation marker Ki67 (E-H) and phosphorylation of Histone 3 on 
Serine 10 (pH3-Ser10, I-L), a marker for mitotic cells. Nuclei of cells are labeled with haematoxylin in 
blue and representative 10x (A-D) and 20x magnified (E-L) images of control (n=3), S100A9-/- (n=3), 
DKO* (n=3) and TKO* (n=6) are shown. 
(M) Epidermal mRNA levels of K6 determined by quantitative PCR analysis.  
(N-Q) Quantification of mouse ear immunohistochemistry displayed in (E-L). Graphs show numbers of 
Ki67 positive (N+P) and pH3-S10-labelled cells (O+Q) cells in the epidermis and the dermis. 
(M-Q) N=3 per genotype, except for TKO* n=6. Data represent mean ± standard deviation and signifi-
cant alterations between groups were calculated using a student t-test and indicated as follows: (*) 
P<0.05, (**) P<0.01 and (***) P<0.001. 
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(DKO* mice) displays an extremely similar phenotype, including rete ridges projecting 
into the dermis as well as scaling (Fig. 2A and (1)). These symptoms are mainly caused 
by abnormal differentiation and uncontrolled hyperproliferation of keratinocytes. Closer 
analysis of keratinocyte differentiation revealed strongly altered skin architecture in 
DKO* mice compared to controls (partially observed in (15)). Keratin 15 (K15) is an epi-
dermal stem cell marker and usually expressed in the hair follicle stem cells of the bulge 
as well as in some keratinocytes of the basal layer ((40) and Fig. 3A). DKO* mice show 
a pronounced downregulation of K15 mRNA levels and strongly reduced number of K15 
expressing cells, especially basal interfollicular keratinocytes, as described for psoriasis 
(41). No alteration in K15-positive cell number and K15 expression was observed in the 
Jun/AP-1 psoriasis mouse model upon loss of S100A9 (TKO* mice), although even 
slightly increased K15 mRNA levels were detected in S100A9-/- versus control animals 
(Fig. 3A-D+Q). In contrast, markers of the basal epidermal layer, keratin 5 (K5) and 14 
(K14), display significant elevation of mRNA levels in DKO* skin compared to controls 
and expression is spread throughout cell layers. Epidermal K5 mRNA levels as well as 
its expression pattern are normalized in TKO* mice (Fig. 3E-H+R). MRNA levels of the 
early differentiation markers keratin 1 (K1) and 10 (K10), which are expressed by spin-
ous layer keratinocytes, are similarly increased in DKO* and TKO* mice versus controls 
(Fig. 3I-L+S). Remarkably, the granular keratinocyte layer expressing the late differen-
tiation marker Loricrin (Lor) and Lor mRNA levels are not only severely reduced in 
DKO*, but rescued to control levels in TKO* mice (Fig. 3M-P+T). Thus, S100A9 loss in 
the Jun/AP-1 psoriasis mouse model leads to normalization of skin architecture and ep-
idermal keratinocyte differentiation.  
Next, we assessed the keratinocyte proliferation marker keratin 6 (K6) and found slightly 
increased mRNA levels in S100A9-/- mice compared to controls, although K6 protein 
localization appeared unchanged and restricted to the hair follicle. In DKO* mice, K6 
mRNA levels were strongly increased and K6 expressed in the interfollicular space 
throughout the epidermis (described in (15)). Interestingly, TKO* mice display a rather 
patchy pattern of K6 expression in the epidermis and overall greatly reduced mRNA 
levels compared to DKO* mice (Fig. 4A-D+M). 
Subsequently, we tested Ki67 (antigen identified by monoclonal antibody Ki-67) for pro-
liferation as well as presence of Serine 10-phosphorylation on Histone 3 (pH3-Ser10), 
an indication for mitosis, by IHC of mouse ears. No alteration was observed in the der- 
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Fig. 5 – Evaluation of apoptosis and cell death in control, S100A9-/-, DKO* and TKO* mice. 
(A-D) Fluorescence images of a TUNEL assay, which marked apoptotic cells in green, performed on 
mouse ear sections. DAPI was used to stain cell nuclei in blue, some TUNEL-positive cells are indi-
cated by white arrows and magnification is 10x. 
(E-F) Numbers of apoptotic cells in the epidermis (E) and the dermis (F) of control (n=3), S100A9-/- 
(n=3), DKO* (n=3) and TKO* (n=6) mice marked by TUNEL as shown in (A-D). 
(G-H) Western blot analysis (H) and quantification relative to β-actin loading control (G) of p53 protein 
levels in epidermal extracts of mice wth indicated genotype are shown (n=2 for control and S100A9-/-, 
n=4 for DKO* and n=7 for TKO* mice). 
(E-G) Data represent mean ± standard deviation. 
(I) Table displaying fold-changes of epidermal mRNA expression levels of BCL2, BAX and Fas as-
sayed by quantitative PCR. N=3 for control, S100A9-/- and DKO* mice and n=6 for TKO* mice. More 
than 2-fold increase is indicated in light green, >5-fold increase in intermediate and >15-fold increase 
in dark green. A decrease is marked in blue, light blue shows a more than 1.5-fold decrease, interme-
diate blue a >2.5-fold and dark blue a >4-fold decrease. 
(E-G+I) Significant alterations between groups were calculated using a student t-test and indicated by 
stars in brackets; (*) represent P<0.05, (**) P<0.01 and (***) P<0.001. 
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mal compartment between all 4 tested genotypes for Ki67 positive cell numbers, but 
pH3-Ser10 positive cells were reduced in DKO* and TKO* mice (Fig. 4E-L+P-Q). 
In the epidermis of DKO* mice, Ki67 and pH3-Ser10 positive cells were found signifi-
cantly elevated and proliferative cells appeared not longer restricted to the basal kerati-
nocyte layer in comparison to controls (partially shown in (15)). In contrast, epidermal 
Ki67 and pH3-Ser10 positive cell numbers were strongly decreased in TKO* versus 
DKO* mice, corresponding to the reduction of epidermal thickening (Fig. 4E-L+N-O). 
Interestingly, apoptosis assayed by quantification of TUNEL (terminal deoxynucleotidyl 
transferase dUTP nick end labeling)-labeled cells is enhanced in the skin of DKO* and 
TKO* mice compared to control and S100A9-/- mice (Fig. 5A-F). An increase of dermal 
TUNEL-positive cells in TKO* mice versus the Jun/AP-1 psoriasis mouse model is de-
tected. Unfortunately, quantitative PCR (qPCR) analysis of the cell death suppressor 
BCL2 (B cell CLL/lymphoma 2) and the apoptosis-inducers BAX (BCL2-associated X 
protein) and Fas (TNF receptor superfamily, member 6) gene transcription in dermal 
extracts failed to produce evaluable values. Consistent with the results obtained by the 
TUNEL assay and previous results in human psoriatic skin (42), epidermal mRNA ex-
pression of BCL2 is reduced in DKO* and TKO* mice versus controls, while mRNA le-
vels of BAX and Fas show no alteration (Fig. 5I). Moreover, we tested protein expres-
sion of the oncogene and apoptosis promoter p53, which has been shown to be overre-
presented in human psoriatic plaques (42) and to control S100A9 expression in oeso-
phageal squamous cell carcinoma (43). Accordingly, we saw overexpression of p53 pro-
tein in epidermal extracts of DKO* mice compared to controls and a normalization in 
TKO* mice (Fig. 5G-H). 
In summary, DKO* mice display epidermal hyperproliferation and strongly altered diffe-
rentiation of keratinocytes as well as increased apoptosis in the skin. Upon loss of 
S100A9 in the Jun/AP-1 psoriasis mouse model (TKO* mice), the number of apoptotic 
cells in the dermis is augmented, whereas keratinocyte proliferation and skin architec-
ture are strongly normalized. S100A9 deficiency itself does not affect keratinocyte proli-
feration or apoptosis comparing S100A9-/- and control mice. Thus, S100A9 is involved 
in the observed, uncontrolled keratinocyte proliferation and differentiation in psoriasis-
like skin disease and its absence in the inflammatory setting lead to reduced symptoms 
in a mouse model. 
 
page 14 
 
3.2. Examination of the blood and lymph vessel network and angiogenic marker 
expression in skin of DKO* and TKO* mice 
 
An enlarged subepidermal vascular network and dilated blood vessels together with an 
influx of various types of immune cells in the surrounding tissue are prominent characte-
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Fig. 6 – Analysis of (lymph-) angiogenesis as well as the vascular network in the Jun/AP-1 pso-
riasis mouse model and the effect of S100A9 loss. 
(A-D) Epidermal and dermal mRNA expression of VEGF A (A), VEGFR1 (B) and VEGFR2 (C) as well 
as of other factors involved in angiogenesis (D) was measured using quantitative PCR of isolates from 
the epidermis of indicated mice (n=3 per group, except for TKO* n=6). Data represent mean ± stan-
dard deviation. Significant alterations between groups were calculated using a student t-test and indi-
cated as follows: (*) P<0.05, (**) P<0.01 and (***) P<0.001. A more detailed explanation on table inter-
pretation (D) is given in Fig. 5I. 
(E-L) Immunofluorescence stainings for LYVE1 (E-H, green channel) and MECA32 (E-H, red channel) 
as well as CD31 (I-L, green channel) were performed on mouse ear sections from control (n=3), 
S100A9-/- (n=3), DKO* (n=3) and TKO* (n=6) mice. Cell nuclei are visualized in blue by DAPI, magni-
fication is 10x. 
 
ristics of chronic inflammation and have been observed in DKO* mice (1). Anti-
inflammatory therapies as well as anti-angiogenic approaches are either widely used or 
promising future-therapies for psoriasis ((44), (15) and (45)). Thus, we assessed vascu-
larization and angiogenesis in DKO* mice upon loss of S100A9 using immunofluores-
cence (IF) and qPCR of mouse ear and tail skin, respectively. A prominent increase of 
VEGF A (vascular endothelial growth factor A), VEGF receptor (VEGFR) 1 and 
VEGFR2 mRNA levels in the epidermis of DKO* compared to control mice (previously 
described in (15)) was reduced in TKO* epidermis (Fig. 6A-D). Then, we analyzed fur-
ther genes involved in angiogenesis (46), like the VEGF co-receptors NRP1 (neuropi-
lin1) and NRP2, VE (vascular endothelial)-Cadherin and TGF (tumor growth factor)-α. 
Moreover, expression of the almost exclusively endothelial cell-restricted receptor TIE2 
(TEK tyrosine kinase, endothelial), which contributes to psoriasis development (47), as 
well as Ang-1 (angiopoietin-1), a TIE2-ligand implicated in angiogenic processes apart 
from that VEGF (48), were tested. By trend, our qPCR results show increased expres-
sion of pro-angiogenic factors in the epidermis and dermis of DKO* versus controls and 
TKO* mice (Fig. 6D). IF for the endothelial cell markers MECA32 (mouse panendotheli-
al cell antigen 32) and CD31 (platelet/endothelial cell adhesion molecule) as well as for 
the lymphangiogenesis marker LYVE-1 (lymphatic vessel endothelial hyaluronan recep-
tor 1) of mouse ears was performed (Fig. 6E-L). The outcome also suggest elevated 
vascularization in the Jun/AP-1 psoriasis mouse model versus controls (previously de-
scribed in (15)) and a decrease in TKO* mice. 
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3.3. The innate and adaptive immune cell infiltrate in the dermis and epidermis of 
TKO* mice determined at different time points 
 
We performed a detailed analysis of changes of the immune cell infiltrate in the skin of 
TKO* compared to DKO* mice at the full blown disease state, two weeks after the last 
tamoxifen injection. In general, a dermal innate cell infiltrate mainly consisting of granu-
locytes, macrophages and mast cells as well as presence of T cells and neutrophils in 
the epidermis are characteristic for psoriasis and have been observed in the skin of 
DKO* mice ((1) and (15)). Staining of mouse ears confirmed presence of increased 
numbers of Gr.1-positive granulocytes, F4/80-positive macrophages and toluidine blue-
labeled mast cells in the dermis of DKO* mice compared to controls. Notably, this cell 
types still infiltrated the dermis of TKO* mice, but to a lesser extend (Fig. 7A-D+I-P+W). 
Neutrophils were labeled by MPO (myeloperoxidase) using IF and readily infiltrate der-
mis and epidermis of both, DKO* and TKO* mice, but are significantly reduced in all 
skin compartments in TKO* versus DKO* mice (Fig. 7E-H+U-V). Further, we assayed 
presence and activation of epidermal Langerhans cells and dermal dentritic cells in the 
ear skin, which express Langerin (Lang) and upon activation also MHCII (mayor histo-
compatibility complex II). The skin of DKO* mice shows significantly increased number 
of resting Lang+ MHCII- and activated Lang+ MHCII+ cells as well as Lang- MHCII+ cells, 
which represent other antigen presenting (APC) cells like dentritic cell subtypes, macro-
phages and B cells in the dermis and activated keratinocytes in the epidermis. Despite 
having similar epidermal Lang+ MHCII- presence, numbers of activated Lang+ MHCII+ 
cells and Lang- MHCII+ cells is reduced in the epidermis and dermis of TKO* compared 
to DKO* mice. No alterations between control and S100A9-/- mice have been observed 
(Fig. 7Q-T+X-Y). Thus, TKO* mice show a significant decrease of APCs accompanied 
by diminished Langerhans and dermal dentritic cell numbers. 
Concerning the infiltration of adaptive immune cells into the skin, we focused on T cells, 
because they are important mediators in psoriasis and only a minor role has been de-
scribed for B cells in the human disease and the Jun/AP-1 psoriasis mouse model ((49), 
(1) and (15)). IHC and IF showed increased numbers of CD3+ (general T cell marker), 
CD4+ (T helper cell marker) and CD8+ (cytotoxic T cell marker) T cells in the dermis of 
DKO* versus control mice and infiltration of those in the epidermis. S100A9-deficiency 
in healthy skin (S100A9-/- mice) did not lead to an alteration of T cell numbers versus  
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Fig. 7 – The innate immune cell infiltrate observed in the skin of DKO* mice is largely dimi-
nished in TKO* mice. 
(A-T) Immunohistochemistry on ear sections of control, S100A9-/-, DKO* and TKO* mice was per-
formed for Gr.1(A-D) and F4/80 (I-L), immunofluorescence for MPO (E-H, green channel), Lang (Q-T, 
green channel) and MHCII (Q-T, red channel) as well as a Toluidine staining (M-P). Some labeled 
cells are marked by arrows (E-F, M-N+P) for better identification and nuclei are either visualized by 
haematoxylin (A-D and I-L) or DAPI staining (E-H and Q-T). Magnification is 10x for (A-L) and 20x for 
(M-T). 
(U-Y) Quantification of labeled cells in the dermis and/or epidermis of stainings shown in (A-T) of con-
trol (n=3), S100A9-/- (n=3), DKO* (n=3) and TKO* (n=6) mouse ear sections are displayed. Data 
represent mean ± standard deviation and significant alterations between groups were calculated using 
a student t-test and indicated as follows: (*) P<0.05, (**) P<0.01 and (***) P<0.001. Significant P-
values <0.05 for quantification of Lang+ MHCII- cells in the epidermis: P= (***) for control vs. DKO*, 
control vs. TKO* and S100A9-/- vs. TKO*; Lang+ MHCII- cells in the dermis: P= (***) for control vs. 
DKO* , S100A9-/- vs. TKO* and DKO* vs. TKO* and P= (*) for control vs. TKO*. Significant P-values 
<0.05 for quantification of Lang+ MHCII+ cells in the epidermis: P= (***) for control vs. DKO*, control 
vs. TKO*, S100A9-/- vs. TKO* and DKO* vs. TKO*; Lang+ MHCII+ cells in the dermis: P= (***) for 
control vs. DKO*, control vs. TKO* and S100A9-/- vs. TKO* and P= (*) for DKO* vs. TKO*. Significant 
P-values <0.05 for quantification of Lang- MHCII+ cells in the epidermis: P= (***) for control vs. DKO*, 
control vs. TKO*, S100A9-/- vs. TKO* and DKO* vs. TKO*; Lang- MHCII+ cells in the dermis: P= (***) 
control vs. DKO* control vs. TKO*, S100A9-/- vs. TKO* and DKO* vs. TKO*. 
 
controls, however TKO* mice have notably reduced CD3+, CD4+ and CD8+ T cell infil-
trates in epidermis and dermis of the ear compared to DKO* mice (Fig. 8A-P).  
Apart from analyzing the cutaneous immune cell presence at the full blown inflammatory 
state, we were interested in determining immune cell infiltration during disease devel-
opment, five days after the last tamoxifen injection (Fig. 9A). Contrary to the fully devel-
oped disease situation, no macroscopical disease symptoms appeared at this early 
stage and the skin integrity was similar between control, S100A9-/-, DKO* and TKO* 
mice (data not shown). We found the total amount of CD3+ T cells as well as relative 
distribution of CD3+ CD4+ T helper cells and CD3+ CD8+ cytotoxic T cells unaltered 
among skin isolates form mice of the four tested genotypes (Fig. 9B-E+N-O). As ex-
pected, also B220+ B cells numbers remained indistinguishable (Fig. 9B-E). However, 
an activation of immune cells/keratinocytes in DKO* and TKO* mice could already be 
observed, as total amount of MHCII+ cells in ear and tail skin cell isolates were in-
creased compared to controls (Fig. 9J-M+P). Remarkably, CD11b+ Gr.1+ granulocyte  
page 19 
 
 
Fig. 8 – T cells are present in the epidermis of TKO* mice, but their numbers are decreased 
compared to DKO* mice. 
(A-L) Ear sections of mice of all four genotypes used in this study (n=3, except for TKO* n=6) were 
immunohistochemically stained for CD3 (A-D) as well as for CD4 (E-H, green channel) and CD8 (I-L, 
green channel) using immunofluorescence. Haematoxylin (A-D) or DAPI (E-L) marked cell nuclei in 
blue and some positively stained cells are indicated by arrows. 
(M-R) Graphs display quantified numbers of labeled cells in the epidermis and dermis of control, 
S100A9-/-, DKO* and TKO* mice form stainings depicted in (E-L). Data represent mean ± standard 
deviation and significant alterations between groups were calculated using a student t-test and indi-
cated as follows: (*) P<0.05, (**) P<0.01 and (***) P<0.001. 
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numbers were significantly elevated in DKO* and TKO* mice versus controls, even at 
this early time point (Fig. 9F-I+Q). Alterations in presence of other CD11b+ myeloid cell 
types, like dentritic cells and macrophages, as well as of activated CD11c+ MHCII+ den-
tritic cells were not detected between control, S100A9-/-, TKO* and DKO* mice (Fig. 9F-
M+R-S). Hence, CD11b+ Gr.1+ granulocytes appear to be the first immune cell type to 
infiltrate the skin during psoriasis development in DKO* mice. This goes along with neu-
trophils, the most abundant type of granulocytes next to eosinophils and basophils, be-
ing in general the earliest detectable leukocytes to appear in an infected aera during an 
immune response. Increased CD11b+ Gr.1+ cell presence in total ear and tail skin iso-
lates at early time points was similar between DKO* and TKO* mice, although a de-
creased dose-dependent responsiveness of isolated S100A9-/- neutrophils upon che-
moattractant stimuli has been described in vitro ((32) and (33)) and S100A8 and A9 pro-
teins are upregulated in the epidermis even 24 hours after three consecutive tamoxifen 
injections (1). Thus, S100A9 is likely to be dispensable for early leukocyte recruitment to 
the skin and inflammation initiation, but rather involved in later disease progression and 
maintenance. 
Taken together, we could show a strongly decreased innate and adaptive immune cell 
infiltration in the skin of TKO* versus DKO* mice at the full blown disease state, while 
S100A9-/- mice showed no changes compared to controls. Thus, as far as analyzed 
here, S100A9 deficiency does not affect a specific immune cell type, e.g. neutrophils or 
marcophages which contain large cytosolic amounts of S100A9. Rather, S100A9 plays 
a role in the amplification of the inflammation in the skin of DKO* mice. 
 
 
3.4. Comparison of cytokine/chemokine levels in sera of control, S100A9-/-, DKO* 
and TKO* mice 
 
Determination of the role of S100A9 on the systemic inflammatory state is crucial, since 
the local immune cell infiltration in the skin of TKO* mice appears strongly reduced ver-
sus DKO* mice. Hence, we examined serum cytokine and chemokine levels by a cyto-
kine array analysis and ELISA (Enzyme-Linked Immunosorbent Assay) and were able 
to reliably detect 31 of 50 tested factors. Serum levels of 11 cytokines/chemokines 
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Fig. 9 – Gr.1-positive cells appear to be the first immune cell type to infiltrate the skin of the 
Jun/AP-1 psoriasis mouse model and TKO* mice during disease development. 
(A) Overview of mouse treatment. JunB
f/f
 c-Jun
f/f
 S100A9
+/-
, JunB
f/f
 c-Jun
f/f
 S100A9
-/-
, JunB
f/f
 c-Jun
f/f
 
S100A9
+/-
 K5-CRE
ERT
 and JunB
f/f
 c-Jun
f/f
 S100A9
-/-
 K5-CRE
ERT
 eight week-old mice were intraperito-
neally injected for 5 consecutive days with 1mg tamoxifen per mouse to induce genomic deletion of 
JunB and c-Jun. Control d5, S100A9-/- d5, DKO* d5 and TKO* d5 mice were sacrificed and analyzed 
five days after the last injection. 
(B-M) Flow cytometric analysis of cells isolated from total ear and tail skin of indicated experimental 
mice (n=2-3 per group). Reperesentative dot plots display distribution of alive single cells stained for 
B220 versus CD3 (B-E); Gr.1 versus CD11b (F-I) and MHCII versus CD11c (J-M). Prior to FACS 
analysis, isolated cells were stained with DAPI to determine viability. 
(N-S) Quantification of FACS data (inter alia) obtained from dot blots displayed in (B-M) of cell isolated 
from total ear and tail skin from control d5, S100A9-/- d5, DKO* d5 and TKO* d5 mice (n=2-3 per 
group). Graphs display percentage of (N) CD3 single positive (CD3+), (O) CD3 CD4 double positive 
(CD3+ CD4+), CD3 CD8 double positive (CD3+ CD8+), (P) MHCII single positive, (Q) CD11b Gr.1 
double positive (CD11b+ Gr.1+), (R) CD11b positive Gr.1 negative (CD11b+ Gr.1-) and (S) CD11c 
MHCII double positive (CD11c+ MHCII+) cells of total isolates. Shown populations were gated on alive 
single cells (N+P-S) or alive single CD3+ cells (O) and cells were stained with DAPI to determine via-
bility prior to flow cytometric analysis. Data represent mean ± standard deviation and significant altera-
tions between groups were calculated using a student t-test and indicated as follows: (*) P<0.05, (**) 
P<0.01 and (***) P<0.001. 
 
(IL (interleukin)-5, IL-13, IL-28b, MCP (monocyte chemotatctic protein)-5, IP-10 (interfe-
ron gamma-induced protein 10)), MIP (macrophage inflammatory protein)-1β, MIP-3α, 
KC (keratinocyte-derived chemokine), TIMP1 (tissue inhibitor of metalloproteases 1), 
fractalkine and EPO (erythropoietin)) were unaltered comparing control, S100A9-/-, 
DKO* and TKO* mice (Fig. 10A). The pro-inflammatory factors IL-7, IL-21, IL-22, IL-25, 
GM-CSF (granulocyte-macrophage colony stimulating factor), M (macrophage)-CSF, 
MIP-1α, MIP-3β and MDC (macrophage-derived chemokine) were elevated in the sera 
of DKO* mice and to an equal extend in TKO* compared to controls (Fig. 10A, F+I). 
These cytokines/chemokines appear to be unaffected by S100A9 loss in the Jun/AP-1 
psoriasis mouse model on a systemic level and, hence, are presumably not involved in 
the S100A9-dependent reduction of inflammatory symptoms in TKO* mice. Eleven in-
flammation-mediating factors, which represent one third of total determined factors in 
mouse sera, were strongly augmented in DKO* sera and significantly reduced to almost 
control levels in the sera of TKO* mice. They include IL-1α, IL-6, IL-12p40, IL-17A and 
IL-27, G (granulocyte)-CSF, MCP-1, MIG (monocyte-induced by gamma-interferon), 
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RANTES (regulated upon activation, normally T-expressed and presumably secreted), 
VEGF and eotaxin (Fig. 10A-E+G-H). All of these cytokines and chemokines were re-
ported to be involved in psoriasis pathogenesis and/or to be upregulated in psoriatic 
skin (IL-1α (50), IL-6 ((51) and (52)), IL-12p40, IL-17A (both (53)), IL-27 (54), G-CSF 
(55), MCP-1 (56), MIG (57), RANTES (58), VEGF ((46) and (15)) and Eotaxin (1)).  
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Fig. 10 – Systemic cytokine and chemokine levels in mouse serum are reduced in TKO* versus 
DKO* mice. 
(A) Serum of experimental mice was taken two weeks after the last tamoxifen injection and cytokine 
array (Millipore) and ELISA analysis was performed to determine cytokine/chemokine levels. Table 
shows fold-change of detected amounts comparing mice of indicated genotype (control (n=3), 
S100A9-/- (n=3-4), DKO* (n=5-6) and TKO* (n=6-8)). A more than 1.8-fold increase is indicated in light 
green and >4-fold increase in dark green. Light blue indicates a more than 1.5-fold decrease and dark 
blue a >2.5-fold decrease. 
(B-I) Graphs show serum levels of the interesting candidates IL-1α (B), MCP-1 (C), RANTES (D), 
VEGF A (E), IL-21 (F), IL-12p40 (G), IL-17A (H) and IL-22 (I) in control, S100A9-/-, DKO* and TKO* 
mice. Data represent mean ± standard deviation. 
(A-I) Significant alterations between groups were calculated using a student t-test and indicated as 
follows: (*) P<0.05, (**) P<0.01 and (***) P<0.001. 
 
In conclusion, the amount of cytokines and chemokines in sera of S100A9-/- and control 
mice appears largely similar. However, levels of numerous pro-inflammatory factors are 
remarkably elevated in sera of DKO* mice and more than half of them were significantly 
reduced in TKO* mice. This could explain diminished immune cell activation and attrac-
tion to skin of these mice (Fig. 7 and Fig. 8). Hence, not only the local immune response 
at affected areas, but the systemic diseased state of DKO* mice is attenuated upon loss 
of S100A9. 
 
 
3.5. Molecular characterization of the skin of the Jun/AP-1 psoriasis mouse model 
upon loss of S100A9 
 
3.5.1. S100 protein family members and S100A8/A9 receptors 
In order to elucidate the role of S100A9 in the context of skin inflammation on a molecu-
lar level, we tested the effect of S100A9 deletion in DKO* mice for mRNA levels of fac-
tors known to be involved in psoriasis. First, we focused on other members of the S100 
family and the receptors of S100A9 and tested their epidermal and dermal mRNA ex-
pression using qPCR as well as protein localization by IHC. Human S100A7, also de-
scribed as psoriasin, belongs to the S100 family of calcium binding proteins and is 
known to be upregulated in psoriasis (59). Epidermal mRNA expression of S100A7A, 
the closest mouse homolog to human S100A7, is increased in DKO* mice, but strongly 
diminished in TKO* mice (Fig. 11A). S100A7A mRNA could not be detected in the der- 
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Fig. 11 – Expression levels of S100 family proteins and their receptors in the skin of the 
Jun/AP-1 psoriasis mouse model and TKO* mice. 
(A) MRNA expression of members of the S100 protein family at their receptors. Table showing fold-
changes of mRNA expression levels of genes in the epidermis and dermis comparing control, 
S100A9-/-, DKO* and TKO* mice (n=3-6), tested by quantitative PCR. A more detailed explanation on 
table interpretation is given in Fig. 5I. 
 (B) Quantification of epidermal cells staining positive for S100A4 in (C). Data represent mean ± stan-
dard deviation, n=3 for control, S100A9-/- and DKO* mice and n=6 for TKO* mice. Significant altera-
tions between groups were calculated using a student t-test and indicated as follows: (*) P<0.05, (**) 
P<0.01 and (***) P<0.001. 
(C) Representative microscopic images of immunohistochemisty for S100A4 of mouse ear sections of 
indicated genotypes. Cell nuclei are stained in blue with haematoxylin, magnification 10x. 
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mis of these mice using qPCR (Fig. 11A). The strong metastasis promoter S100A4, 
mainly known as metastasin (60), has also been associated with psoriasis (61). In ac-
cordance with previous findings for human skin, S100A4 mRNA expression in the der-
mis was increased in the Jun/AP-1 psoriasis mouse model compared to controls and 
normalized in TKO* mice (Fig. 11A). Also IHC of mouse ears for S100A4 protein 
showed elevated numbers of labeled cells, which are most likely Langerhans cells, in 
the epidermis of DKO* mice and a significant reduction upon loss of S100A9 was ob-
served (Fig. 11B-C). 
Next, we tested S100A3, which appears to be involved in differentiation of epithelial 
cells in the hair follicle ((62) and (63)), by qPCR and found its mRNA levels highly re-
duced in all skin compartments of DKO* mice (Fig. 11A). S100A3 appears to be in-
creased in S100A9-/- mice, showing an antagonistic mRNA expression pattern of 
S100A3 to S100A8 and S100A9 (Fig. 11A and personal communication P. Angel, DKFZ 
Heidelberg). Independently, S100A10 and S100A16 proteins have been found to be 
differentially regulated in the epidermis of control, S100A9-/-, DKO* and TKO* mice 
(H. Schönthaler, unpublished observation). S100A10 has largely been associated with 
inflammation (64) and may be involved in membrane remodeling during keratinocyte 
differentiation (38). Epidermal S100A10 mRNA levels were downregulated to the same 
extend in DKO* and TKO* mice (Fig. 11A). However, mRNA expression of S100A16, 
which appears elevated in various human tumors (65), was found to be increased in the 
epidermis of S100A9-/- and TKO*, but not DKO* mice compared to controls (Fig. 11A). 
S100A1, which is not directly associated with psoriasis (66), showed no pronounced 
alteration in mRNA expression in the dermis and epidermis among control, S100A9-/-, 
DKO* or TKO* mice in a qPCR analysis (Fig. 11A). 
No changes in mRNA levels in the epidermis of mice of all four analyzed genotypes 
were obtained for the S100A8 and S100A9 receptors Scarb1 (Scavenger receptor class 
B member 1) and Scarb2, also known as CD36 (67), and RAGE (Receptor for Ad-
vanced Glycosylation End products), which is required for S100A8/A9 upregulation in 
an inflammatory setting (68) (Fig. 11A). In the dermis of S100A9-deficient mice, 
S100A9-/- and TKO*, mRNA levels of RAGE were increased compared to controls, but 
unaffected in DKO* mice (Fig. 11A). Thus, the reduced inflammatory symptoms of 
S100A9-loss in the psoriasis mouse model could not be associated with expression 
changes of the S100A8/A9 receptors Scarb1, Scarb2 and RAGE. 
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In contrast, qPCR analysis of mRNA expression revealed strong elevation of the 
Toll-like receptor TLR4, which is also a receptor for S100A8/A9 (17), as well as its 
adaptor protein MyD88 (myeloid differentiation primary response gene 88) in the epi-
dermis (and dermis) of DKO* mice and normalization in TKO* mice compared to con-
Fig. 12 – Analysis of deregulation of TNFα pathway components in the epidermis and dermis 
control, S100A9-/-, DKO* and TKO* mice. 
(A) MRNA expression of factors involved in TNFα-mediated signaling. Table showing fold-changes of 
mRNA expression levels of genes in the epidermis and dermis comparing mice of the four genotypes 
used in this study, tested by quantitative PCR. A more detailed explanation on table interpretation is 
given in Fig. 5I. 
(B) Quantification of Western blot analysis shown in (C) of p38α protein levels in the epidermis of indi-
cated mice. Graph displays the amount of phosphorylated p38α (p-p38α) relative to total p38α. Data 
represent mean ± standard deviation, n=2-4 per genotype and P>0.05 among all values. No significant 
difference was observed comparing total p38α levels in the epidermis of control, S100A9-/-, DKO* and 
TKO* mice. 
(C) Western blot analysis of p-p38α and total p38α levels in the epidermis of mice with indicated geno-
types. Protein of JunB
Δep*
 epidermis, which has been described to have elevated p-p38α levels ((12), 
provided by Ö. Uluçkan), served as positive control (+) and Ø represents no loaded protein. Loading 
control was β-actin. 
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trols (Fig. 11A). This can be explained by upregulation of TLR4 by keratinocytes (69) 
and the fact that TLR4 is present on the cell surface of many types of immune and in-
flammation-associated cells, e.g. on neutrophils, which infiltrate the skin of DKO* mice. 
 
3.5.2. TNF pathway associated genes 
Main mediators of inflammation and psoriasis, such as tumor necrosis factor (TNF) α 
and its receptors TNFR1 and TNFR2 ((70) and (14)), are notably downregulated in the 
epidermis and dermis of TKO* compared to DKO* mice on mRNA level, but unaffected 
upon S100A9 deficiency in normal skin (Fig. 12A). Induced TNFα production in human 
keratinocytes has been described to be p38α-dependent (71), however mRNA and 
p38α protein phosphorylation levels analyzed by Western blot were unaltered in epi-
dermis of control, S100A9-/-, DKO* and TKO* mice (Fig. 12A-C). The mechanism lead-
ing to TNFα membrane shedding is mediated by TACE (TNFα Converting Enzyme, 
(14)). As previously described in human psoriatic plaques (72), elevated epidermal 
TACE mRNA levels were detected in the epidermis of the Jun/AP-1 psoriasis mouse 
model and also TKO* mice (Fig. 12A). Expression of the JunB/c-Jun protein target and 
Fig. 13 – The Th17 axis in the Jun/AP-1 psoriasis mouse model and altered expression of in-
volved factors upon S100A9 loss. 
(A) Table showing fold-changes of mRNA expression levels of components associated with the T hel-
per (Th)-17 cells in the epidermis and dermis of indicated mice, tested by quantitative PCR. A more 
detailed explanation on table interpretation is given in Fig. 5I. 
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TACE inhibitor TIMP3 (Tissue Inhibitor of Metalloproteases 3, (14)) is significantly 
downregulated in DKO* as well as in TKO* skin in comparison to controls (Fig. 12A and 
(15)). Thus, the reduction of TNFα expression in the Jun/AP-1 psoriasis mouse model 
upon loss of S100A9 appears to be p38α and TIMP3/TACE independent. 
 
3.5.3. Factors involved in the Th17/IL-23 axis in psoriasis 
T helper (Th) cells are considered to play an important role in psoriasis, especially the 
recently described sub-population of IL-17-producing Th17 cells (73) has been asso-
ciated with disease pathogenesis (53). Stimulation with several inflammation-mediating 
cytokines like IL-21 together with TGF-1 (tumor growth factor 1) induces naïve T cells 
to express IL-23R (IL-23 receptor). Subsequently, binding of IL-23, a heterodimer of the 
IL-23p19 and IL-12p40 subunits, causes phosphorylation of the transcription factor 
STAT3 (Signal Transducer and Activator of Transcription 3) and expression of cytokines 
like IL-17A, IL-17F and IL-22 by Th17 cells (53). We observed mRNA levels of almost 
all mentioned cytokines involved in the Th17 axis to be significantly elevated in the skin 
of DKO* mice versus controls (Fig. 13A, (1) and (15)). Transcription of IL-23p19 and IL-
12p40, the subunits of the cytokine mediating Th17-differentiation IL-23, were found 
unaltered in TKO* compared to DKO* dermis on mRNA level. Dermal mRNA expression 
of IL-23 subunits is already increased in S100A9-/- mice without additional inflammatory 
stimulus compared to controls (Fig. 13A-E). Nevertheless, TKO* mice display norma-
lized transcription of IL-23R, which is expressed by Th17 cells, in epidermis and dermis 
compared to DKO* mice (Fig. 13A-E). Also, we detected decreased mRNA levels of 
cytokines produced by Th17 cells (IL-17A, IL-17F and IL-22) in the skin upon loss of 
S100A9 in DKO* mice (Fig. 13A). It is necessary to mention at this point, that IL-17A, 
IL-17F and IL-22 are not exclusively released by Th17 cells. In fact, IL-22 is also pro-
duced by NK and NKT cells (74) and γδ-T-, NK- and NKT cell-derived IL-17A/F appears 
crucial for several inflammatory responses (75). Moreover, IL-17A might be secreted by 
keratinocytes upon stimulation (Ö. Uluçkan, unpublished observation). 
Elevated mRNA levels of several Th17-associated cytokines and factors were observed 
in DKO* compared to healthy mouse skin. Moreover, an analysis for Th17/IL-23 related 
cytokines in the serum showed similar results (Fig. 10A, F-I). These results suggest a 
high Th17 cell presence in the skin of the Jun/AP-1 psoriasis mouse model, which is at 
least partially dependent on S100A9. 
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3.5.4. Local cytokine and chemokine expression in mouse skin 
The interplay between keratinocytes and immune cells is crucial for skin inflammation 
and psoriasis pathogenesis. In order to elucidate the impact of S100A9 on the produc-
tion of cytokines/chemokines involved in inflammation in the skin, we performed a can-
didate screen of mRNA expression levels in the epidermis and the dermis of control, 
S100A9-/-, DKO* and TKO* mice. 
No significant mRNA expression changes of IL-11 and IL-20 were observed in the skin 
of mice of all four tested genotypes (Fig. 14A), although IL-11 protein was reported to 
be released by skin biopsy cultures (76) and IL-20 mRNA levels to be elevated in pso-
riatic skin ((77) and (78)). IL-1ra (IL-1 receptor antagonist), IL-9 and IL-13 were signify- 
 
Fig. 14 – Differential expression of cytokines and chemokines in the skin of the Jun/AP-1 pso-
riasis mouse model upon S100A9 loss. 
(A) Table shows fold-change of mRNA expression levels in the epidermis and dermis comparing con-
trol, S100A9-/-, DKO* and TKO* mice, tested by quantitative PCR. N=3 for control, S100A9-/- and 
DKO* mice and n=6 for TKO* mice. Significant alteration of levels between mice of two tested geno-
types is indicated by stars in brackets; (*) represent P<0.05, (**) P<0.01 and (***) P<0.001 significance 
in a student t-test. A more detailed explanation on table interpretation is given in Fig. 5I. 
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cantly elevated in the epidermis of DKO* and TKO* mice compared to controls 
(Fig. 14A). Thus, these cytokines are likely to contribute to the psoriasis-like phenotype 
in a S100A9-independent manner. IL-1β, IL-6, MIP-1α, MIP-1β, MIP-2, GRO-1 (mela-
noma growth stimulating activity 1) and IP-10 (interferon gamma-induced protein 10) 
were significantly upregulated as well as IL-18 and IL-20 receptor (IL-20R) downregu-
lated in the epidermis and mostly also in the dermis of DKO* mice, as partly reported 
previously ((1) and (15)) and similar described for human psoriatic skin ((79), (52) and 
(78)). Importantly, epidermal (and dermal) mRNA expression of all eight cyto-
kines/chemokines was normalized in TKO* mice (Fig. 14A), suggesting S100A9-
dependent regulation of these factors in the skin. Hence, S100A9-deficiency in the set-
ting of skin inflammation appears to cause an overall normalization of epidermal and 
dermal mRNA expression of tested cytokines and chemokines. 
 
3.5.5. Factors associated with psoriasis 
Various other proteins have been implicated in psoriasis pathogenesis and described to 
be differentially regulated in psoriatic skin. To perform a closer molecular characteriza-
tion of the skin of TKO* mice compared to the Jun/AP-1 psoriasis mouse model, we 
tested the cutaneous expression of selected candidate genes by qPCR. 
EGF (Epidermal Growth Factor) is a potent inducer of keratinocyte proliferation and its 
concentration has been shown to be increased in psoriatic patients in the serum (80), 
while EGFR (EGF receptor) is considered to be a potential target in psoriasis treatment 
(81). PDGF (Plateled-Derived Growth Factor) was described to be overexpressed in the 
dermis of psoriasis patients (82) as well as IGF (Insulin-like Growth Factor)-1 to be 
upregulated in psoriatic epidermis (83). Analysis of epidermal mRNA expression re-
vealed no remarkable changes in EGF, EGFR, IGF-1, PDGF-A and PDGFRα (PDGF 
receptor α) levels in control, S100A9-/-, DKO* and TKO* mice, while PDGFRβ was sig-
nificantly augmented in DKO* compared to control and TKO* mice (Fig. 15A). However, 
analysis of protein expression in the skin and receptor tyrosine kinase activation by 
phosphorylation will be necessary to interpret the relevance of the mentioned growth 
factors and their receptors in the Jun/AP-1 psoriasis mouse model and TKO* mice. 
MMPs (Matrix metalloproteases) are a large family of mediators of inflammation and 
tissue repair and are controlled by TIMPs (Tissue Inhibitor of Metalloproteases). 
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Elevated serum levels of TIMP1 (84) as well as increased expression of MMP9 (85), 
MMP2 and TIMP2 (86) in the skin of psoriasis patients were reported. MMP2 and 
TIMP2 epidermal expression remained unaltered comparing the four genotypes used in 
Fig. 15 – Determination of expression levels of factors associated with psoriasis in control, 
S100A9-/-, DKO* and TKO* mice. 
(A) Table showing fold-changes of mRNA expression levels of growth factors and their receptors, ma-
trix metalloproteases (MMPs) and their inhibitors (TIMPs), prostaglandins and their receptors as well 
as other factors implicated in psoriasis pathogenesis. Epidermal isolates of mice of all four genotypes 
used in this study were analyzed by quantitative PCR. A more detailed explanation on table interpreta-
tion is given in Fig. 5I. 
(B) Immunohistochemistry for phosphorylated STAT3 (pSTAT3) of cut mouse ear sections of control 
(n=3), S100A9-/- (n=3), DKO* (n=3) and TKO* mice (n=6). Cell nuclei are stained in blue with haema-
toxylin, representative images are shown and magnification is 10x. 
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this analysis, while MMP8, MMP9 and TIMP1 mRNA levels were significantly aug-
mented in the epidermis of DKO* and normalized in TKO* mice (Fig. 15A). However, 
TIMP1 protein on a systemic level in mouse sera showed no change between control, 
S100A9-/-, DKO* and TKO* mice (Fig. 10A).  
Finally, we analyzed mRNA expression by qPCR of further factors and markers asso-
ciated with either psoriasis, skin inflammation or keratinocyte proliferation. PTGS2 
(Prostaglandin E2) is overexpressed in human psoriatic skin (87) as well as in the epi-
dermis of DKO* and normalized in TKO* mice (Fig. 15A). Whereas PTGS1 (Prostaglan-
din E1) as well as PTGER (Prostaglandin E receptor)-1, PTGER2, PTGER3 and 
PTGER4 epidermal mRNA levels remain unaltered in control S100A9-/-, DKO* and 
TKO* mice (Fig. 15A). 
CD44, the receptor for hyaluronic acid which binds MMPs, is reported to be upregulated 
in human psoriatic skin (88) as well as Calm1 (Calmodulin 1, (89)), which was also 
found to be augmented in the Jun/AP-1 psoriasis mouse model (1). Also Slpi (Secretory 
Leukocyte Protease Inhibitor), whose expression is increased in keratinocytes upon in-
flammation (90), was described to be upregulated in DKO* mice (1). Moreover, phos-
phorylation of STAT3 (pSTAT3) in keratinocytes is associated with increased prolifera-
tion (91) and mice expressing a constitutively active STAT3 under control of the K5 
promotor develop a skin irritation similar to human psoriasis (92). Indeed, qPCR analy-
sis revealed increased mRNA levels of CD44, Calm1, Slpi and STAT3 in the epidermis 
of DKO* mice compared to controls. While the levels of CD44 and Calm1 remained un-
altered between DKO* and TKO* mice, Slpi and STAT3 mRNA was significantly de-
creased (Fig. 15A). Furthermore, the number of pSTAT3 positive cells appears elevated 
in the epidermis of the DKO* mice versus controls and reduced in TKO* epidermis 
(Fig. 15B).  
Levels of the scaffolding protein Cav1 (Caveolin1), known to be reduced in psoriatic 
plaques (93), and the keratinocyte proliferation inhibitor TGF-β2 were previously ob-
served to be downregulated in the Jun/AP-1 psoriasis mouse model (1). We were able 
to confirm this finding and, additionally, observed an increase to almost control mRNA 
levels in TKO* mice (Fig. 15A). These results show that DKO* mice display a highly 
similar expression pattern of psoriasis-associated genes to the human situation and that 
these factors are mostly normalized after the deletion of S100A9. 
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Fig. 16 – In vitro system used for adenoCre mediated deletion of JunB and c-Jun in primary 
keratinocytes. 
(A) Schematic view of procedure of adenovirus application to primary keratinocytes for different time 
periods. 
(B) Overview of mice used for keratinocytes isolation. Keratinocytes derived from JunB
f/f
 c-Jun
f/f
 
S100A9
+/-
 and JunB
f/f
 c-Jun
f/f
 S100A9
-/-
 mice were either treated with an adenovirus carrying GFP 
(adenoGFP) to obtain control and S100A9-/- keratinocytes (KCs) or an adenovirus carrying Cre re-
combinase (adenoCre) to produce DKO* and TKO* keratinocytes.  
(C-G) Western blot analysis and quantification of JunB (D), c-Jun (E), S100A8 (F) and S100A9 (G) 
protein levels in keratinocytes of the indicated genotype exposed to adenovirus for 24, 48, 72 or 96 
hours. Protein level quantification was performed relative to the loading control -actin in (D-G). One 
representative experiment per time period of adenovirus treatment of is displayed. 
(H-K) Representative bright-field image of control, S100A9-/-, DKO* and TKO* keratinocytes (KCs) 
exposed to adenovirus for 96 hours, magnification is 20x. 
(L-O) Immunocytofluorescence for c-Jun (red channel) of keratinocytes with indicated genotypes 
treated with adenovirus for 72 hours is shown. Cell nuclei were stained with DAPI in blue, white ar-
rows mark some c-Jun-positive nuclei and magnification is 20x. 
 
3.6. Determination of cell autonomous proliferation behavior of in vitro-deleted 
JunBΔep* c-JunΔep* S100A9+/- (DKO*) and JunBΔep* c-JunΔep* S100A9-/- (TKO*) kerati-
nocytes 
 
In order to determine possible cell autonomous effects of S100A9 deficiency in kerati-
nocytes, we employed a cell culture system and in vitro deletion of JunB and c-Jun us-
ing an adenovirus (Fig. 16A). Primary keratinocytes were isolated from ear and tail skin 
of JunBf/f c-Junf/f S100A9+/- and JunBf/f c-Junf/f S100A9-/- mice and cultured under pres-
ence of adenovirus containing Cre recombinase (adenoCre) for Jun protein deletion to 
obtain DKO* and TKO* keratinocytes or green fluorescent protein (adenoGFP) to obtain 
control and S100A9-/- keratinocytes (Fig. 16B). When testing for the optimal virus con-
centrations (150, 300 and 600 particles/cell), we detected highest JunB and c-Jun dele-
tion efficiency using 600 particles/cell of adenoCre (data not shown). Primary keratino-
cytes were incubated for 24, 48, 72 and 96 hours with the respective adenovirus to in-
crease the extent of Jun gene deletion in keratinocytes (Fig. 16A). More than 3-fold 
downregulation of JunB and c-Jun protein levels in DKO* and TKO* keratinocytes com-
pared to control and S100A9-/- keratinocytes were already observed after 48 hours and 
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longer adenoCre exposure by Western blot analysis (Fig. 16C+D-E) and immunocytof-
luorescence for c-Jun after 72 hours adenoCre infection of keratinocytes (Fig. 16L-O). 
As expected, DKO* keratinocytes incubated with adenoCre for 72 hours or longer 
showed a more than 50% increase in S100A8 and S100A9 protein expression versus 
controls (Fig. 16C+F-G and (1)). Keratinocyte cell shape and density assessed by 
bright-field microscopy of cultures appear similar between control, S100A9-/-, DKO* and 
TKO* keratinocytes (Fig. 16H-K). 
Fig. 17 – Proliferation of primary, in vitro-deleted DKO* and TKO* keratinocytes is unaltered 
compared to controls. 
(A) Proliferation of primary keratinocytes was determined by an EdU incorporation assay after an EdU 
pulse for 1 to 6 hours, depending on the time the cells were cultured. Percentage of EdU positive con-
trol, S100A9-/-, DKO* and TKO* keratinocytes (KCs) exposed to adenovirus for the indicated period is 
depicted. Analysis was performed according to manufacturer’s instructions, by staining for EdU and 
DAPI, to determine DNA content, and subsequent flow cytometric quantification.  One representative 
experiment per time point is shown, data represent mean of duplicates or triplicates. 
(B-E) Representative dot blots of flow cytometric evaluation of EdU incorporation versus DNA content 
(determined by DAPI staining) by keratinocytes of indicated genotypes after 72 hours of adenovirus 
incubation are shown. 
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DKO* mice showed a much stronger epidermal hyperproliferation than TKO* mice 
(Fig. 4), suggesting involvement of S100A9 in keratinocyte proliferation. By in vitro stu-
dies, we wanted to determine the possible cell autonomous role of S100A9 in keratino-
cytes. Cell proliferation of in vitro deleted primary keratinocytes was determined by an 
EdU (5-ethynyl-2´-deoxyuridine) incorporation assay. The thymidine nucleoside analog 
EdU was incorporated in newly synthesized DNA of cultured primary keratinocytes and 
cells in G1/G0, S and G2 phase could be determined by flow cytometric analysis, 
(Fig. 17B-E). No difference in EdU-positive cell numbers between control, S100A9-/-, 
DKO* and TKO* keratinocytes after 24h, 48h, 72h and 96 hours adenovirus or ade-
noGFP exposure was detected (Fig. 17A). 
This outcome indicates that increased epidermal proliferation in DKO* mice is no cell 
autonomous effect of genetic deletion of JunB and c-Jun in keratinocytes and S100A9 
appears to be dispensable for keratinocyte proliferation in vitro. Most likely, epidermal 
thickening and elevated keratinocyte proliferation in DKO* mice is a result of the inter-
play between several cell types and keratinocytes in the skin leading to a psoriasis-like 
skin disease. 
 
 
3.7. Identification of S100A9-dependent factors produced by keratinocytes, me-
diating the cross talk to immune cells in skin 
 
S100A9 loss strongly reduces the overall psoriatic phenotype of DKO* mice (Fig. 2) and 
we found a diminished amount of inflammatory cytokines on a systemic level in the sera 
of TKO* compared to DKO* mice (Fig. 10). Thus, we aimed to identify S100A9-
dependent, keratinocyte-derived mediators of the immune cell - keratinocyte interplay 
by evaluating cytokine / chemokine levels in the supernatant of in vitro deleted control, 
S100A9-/-, DKO* and TKO* keratinocytes after 96 hours-adenovirus exposure (Fig. 16) 
using a cytokine array and ELISA analysis. 
We measured reliable levels of 14 cytokines and chemokines in the supernatant of pri-
mary control, S100A9-/- keratinocytes and in vitro-deleted DKO* and TKO* keratino-
cytes. Five of these factors (IL-1α, IL-25, MCP-5, LIX (Lipopolysaccharide-Induced CXC 
chemokine) and VEGF) were unchanged comparing keratinocytes of all four genotypes 
(Fig. 18A-B). Elevated levels of more than half of detectable factors in keratinocyte-
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conditioned supernatant were observed in DKO* keratinocytes compared to controls, 
underlining the activation of keratinocytes through JunB/c-Jun deletion. G-CSF, M-CSF, 
MCP-1, MIP-2, MIP-3α, KC and TIMP1 exhibited a similarly increased amount in super-
natant from TKO* and DKO* keratinocytes (Fig. 18A+C). However, LIF (leukemia inhibi-
Fig. 18 – Cykokines and chemokines secreted by keratinocytes after deletion of JunB and 
c-Jun and/or S100A9-deficiency in vitro. 
(A) Isolated, primary keratinocytes were treated with adenoCre or adenoGFP for 96 hours to obtain 
control, S100A9-/-, DKO* and TKO* keratinocytes, the medium changed and keratinocyte-conditioned 
supernatant collected after 24 hours. Multiplex and ELISA analysis was performed to determine cyto-
kine/chemokine levels shown as fold-change of detected amounts comparing keratinocytes of indi-
cated genotype (n=2 per group) in a table. A more detailed explanation on table interpretation is given 
in Fig. 10A. 
(B-E) Selected examples of cytokines with unchanged IL-1α (B) and increased secreted MCP-1 (C) 
levels by DKO* and TKO* keratinocytes.  The amount of LIF (D) and RANTES (E) in supernatant of 
TKO* was reduced compared to DKO* keratinocytes. Data represent mean ± standard deviation. 
(A-E) Significant alterations between groups were calculated using a student t-test and indicated as 
follows: (*) P<0.05, (**) P<0.01 and (***) P<0.001. 
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tory factor) and RANTES levels were reduced in TKO* keratinocytes compared to DKO* 
keratinocytes (Fig. 18A+D-E). LIF was below detection threshold in mouse serum, but 
RANTES also showed significantly elevated serum levels in DKO* mice and a normali-
zation upon loss of S100A9 (Fig. 10A+D). These results indicate that LIF and RANTES 
production and/or secretion by keratinocytes might be positively regulated by S100A9 in 
a cell autonomous manner, whereas strong chemotactic proteins like G-CSF, M-CSF, 
MCP-1 and MIP-2 appear not to be. 
In summary, in vitro deletion of JunB and c-Jun in keratinocytes leads to an increase in 
secretion of several chemotactic and pro-inflammatory factors in a cell-autonomous 
manner. Although S100A9 is upregulated in keratinocytes upon JunB and c-Jun dele-
tion (1), S100A9 seems to have only a minor cell autonomous effect on secretion of 
other cytokines/chemokines by keratinocytes, since protein levels in supernatant from 
DKO* and TKO* keratinocytes appear largely similar. Nevertheless, LIF and RANTES 
supernatant levels are reduced in TKO* keratinocyte-conditioned medium compared to 
DKO* keratinocytes, representing interesting candidates for further analysis. 
 
 
3.8. Transgenic expression of S100A8/A9 to induce skin inflammation 
 
The S100A8 and S100A9 proteins are only weakly expressed in healthy epidermis and 
strongly upregulated by activated keratinocytes during skin pathologies (38), including 
inflammation-driven skin carcinogenesis (94), wound healing (23) and psoriasis (37). 
We aimed to reproduce an inflammatory state of the skin by inducible, transgenic ex-
pression of S100A8 and S100A9 proteins using the Tet-ON system in keratinocytes in a 
mouse model. Mice carrying a S100A8-IRES-S100A9-Myc knock-in allele 
(tgS100A8/A9) inserted downstream of a tet-Operator (tetO) downstream of the Colla-
gen A1 locus (H. Schönthaler, P. Angel, G. Beranger, L. Bakiri and (95)) and a ROSA- 
or K5-controlled tetracycline transactivator (rtTA) were tested for proper transgene inte-
gration by Southern blot (Fig. 19A). Administration of doxycycline (DOX) renders rtTA 
protein capable of binding the tetO and activates transcription of S100A8 and S100A9. 
DOX was given to tgS100A8/A9KI/+ ROSA-rtTAT/+ (S100A8/A9-rosa-tetON), 
tgS100A8/A9KI/+ and ROSA-rtTAT/+ mice (the last two being controls) in drinking water 
(0.5 gram/liter) from birth, weaning or 7 weeks of age (in the resting phase of the hair  
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Fig. 19 – S100A8/A9-rosa-tetON mice do not show consistent increase of S100A8 or S100A9 
protein levels. 
(A) Southern blot showing correct integration of the S100A8-IRES-S100A9-Myc transgene in the Col-
lagenA1 (ColA1) locus. Total DNA from mouse tail was SpeI digested and a 3’ probe used for detec-
tion of flp-in allele at 4.1kb, wildtype allele at 6.2kb and frt allele at 6.7kb as described in (95). The 
following mice were used: four mice generated by blastocyst injection with transgenic embryonic stem 
cells, one of them negative (negative) and three chimeric for the S100A8/A9 transgene (chimera 1-3) 
as well as one second generation offspring (F2 generation) after germ-line transmission. C57BL/6 
mice served as negative control (wildtype) and DNA from a mouse carrying a Fra1 transgene inte-
grated in the ColA1 locus as positive control (positive, provided by S. Hasenfuss). 
(B) Treatment of control and S100A8/A9-rosa-tetON mice with 0.5g DOX in drinking water was started 
at birth, weaning or seven weeks of age and proceeded for 12 weeks before sacrifice and analysis, 
except for the early transgene expression experiment. Here mice were sacrificed after 2, 4 or 7 days 
of DOX administration. 
(C-D) Western blot (C) of protein isolates from control and S100A8/A9-rosa-tetON mice (12 weeks 
DOX induction started at 7 weeks of age) for S100A8 and S100A9 in tail epidermis and spleen and 
quantification (D). Data represent mean ± standard deviation (n≥6 per group). No significant altera-
tions were determined between groups using a student t-test. 
(E-F) H&E staining of spleen (E) and backskin (F) of mice with indicated genotype (12 weeks DOX 
induction started at 7 weeks of age), magnification 10x. Inserts in (F) show higher magnification of 
epidermis. 
(G-H) Analysis of S100A8 and S100A9 expression by Western blot (G) in epidermis of tail and back-
skin of control and S100A8/A9-rosa-tetON mice 2-7 days on DOX, started at 7 weeks of age and 
quantification (H, n=1 per condition). 
 
cycle) for 12 weeks (Fig. 19B). No macroscopic phenotype of mice induced by DOX 
administration at birth (n≥2 per group), weaning (n≥2 per group) or 7 weeks of age (n≥6 
per group) was apparent. We analyzed S100A8 and S100A9 protein levels in mice 
treated with DOX from 7 weeks of age and no consistent increase in tail dermis, lung, 
muscle, liver (n=2 per group, data not shown), tail epidermis and spleen (Fig. 19C+D) of 
S100A8/A9-rosa-tetON mice versus control was observed. We obtained similar results 
testing mRNA levels of S100A8/A9 in several tissues in these mice (n≥6, data not 
shown). Analysis of H&E-stained spleen and backskin sections from S100A8/A9-rosa-
tetON mice did also not show any histological alterations in (Fig. 19E+F). 
Additionally, we checked for transgene induction after 2, 4 and 7 days of DOX treatment 
of 7-weeks old mice (Fig. 19B). However, upregulation of S100A8 or S100A9 mRNA or 
protein levels in tail or backskin epidermis of S100A8/A9-rosa-tetON mice compared to 
controls was not detected (Fig. 19G+H). 
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Then, we induced S100A8/A9 expression by DOX administration for 4, 8, 24, 48 and 72 
hours in vitro in primary keratinocytes isolated from tgS100A8/A9KI/+ (control) and 
tgS100A8/A9KI/+ ROSA-rtTAT/+ (S100A8/A9-rosa-tetON) mice (Fig. 20A). No elevation of 
S100A8 or S100A9 protein levels (Fig. 20B) or altered proliferation behavior due to 
possible activation of keratinocytes was observed (Fig. 20C). 
Next, we analyzed mice carrying an rtTA under the control of the K5 promotor, to test if 
S100A8/A9 knock-in allele expression can be observed specifically in the skin using a 
different rtTA mouse line. At 7 weeks of age tgS100A8/A9KI/+ K5-rtTAT/+ (S100A8/A9-k5-
tetON), tgS100A8/A9KI/+ and K5-rtTAT/+ mice (the last two being controls) were adminis-
Fig. 20 – Analysis of S100A8/A9-rosa-tetON keratinocytes induced by doxycycline in vitro for 
expression of S100A8 and S100A9. 
(A) Overview on treatment of primary keratinocytes isolated from control and S100A8/A9-rosa-tetON 
mice. DOX (1µg/ml) was added to culture medium for different time periods, as indicated. 
(B) Levels of S100A8 and S100A9 protein in control and S100A8/A9-rosa-tetON keratinocytes in-
duced by DOX of the specified period determined by Western blot. 
(C) Graph shows percentage of EdU positive cells after EdU incorporation assay for elucidation of 
proliferation behavior with 1-2 hours EdU pulse. 
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tered DOX in drinking water for 12 weeks. However, induced expression of S100A8 and 
S100A9 on mRNA and protein level was not observed in tail epidermis (n=5 per geno-
type, data partially shown in Fig. 21A). As a control, the spleen of S100A8/A9-k5-tetON 
mice was taken and S100A8/A9 protein levels did not show an alteration compared to 
control mice (n=5 per genotype, Fig. 21A). Also, no reliable increase of S100A8 or 
S100A9 protein expression could be detected during early transgene induction after 2, 4 
or 7 days DOX treatment of 7-weeks old mice in epidermis of tail or backskin (Fig. 21B). 
Moreover, primary keratinocytes isolated form tgS100A8/A9KI/+ k5-rtTAT/+ mice did not 
show an upregulation of S100A8 or S100A9 upon 24 hours stimulation with increasing 
concentrations of DOX compared to tgS100A8/A9KI/+ and k5-rtTAT/+ (both controls) or 
untreated keratinocytes (Fig. 21C). 
No elevation of S100A8 and S100A9 mRNA (data not shown) and protein amount could 
be induced by ectopic expression of the S100A8-IRES-S100A9-Myc knock-in allele us-
Fig. 21 – No S100A8 and S100A9 protein elevation was detected in epidermis and isolated kera-
tinocytes of DOX-treated S100A8/A9-k5-tetON mice.  
(A-C) Western blots analysis of tail epidermis, backskin epidermis and/or spleen of S100A8/A9-k5-
tetON mice and littermate controls treated with DOX from 7 week of age for 12 weeks (A) or 2-7 days 
(B) as well as primary keratinocytes induced with DOX for 24 hours (C) for S100A8 and S100A9 ex-
pression. 
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ing the tetON system at steady-state conditions in mouse skin. Although we were una-
ble to observe changes on total S100A8 or S100A9 levels, we were able to detect pres-
ence of transgenic S100A8/A9 mRNA in tail epidermis of S100A8-A9 k5-tetON mice 
using qPCR with primers detecting only the transgene (n≥5, data not shown), indicating 
transcription of tgS100A8/A9. 
Hence, we hypothesized S100A8/A9 mRNA and/or protein might be unstable and their 
levels tightly regulated without additional challenge. Therefore, we decided to stimulate 
the skin with TPA (12-O-tetradecanoyl-13-phorbolacetate), which not only causes in-
flammation but also induces S100A8 and S100A9 expression (68), to eventually obtain 
increased response of S100A8-A9 k5-tetON mice. After 3.5 weeks of DOX administra-
tion, which was started at 7 weeks of age, 100µl of acetone or 100µl of 0.1µM TPA dis-
solved in acetone was topically applied on freshly shaved backskin of S100A8/A9-k5-
tetON and control mice (Fig. 22A). Strong elevation of S100A8 and S100A9 protein le-
vels was observed in total backskin 24 and 96 hours after TPA treatment compared to 
untreated mice. However, no induction or increased stabilization of S100A8 and 
S100A9 expression was determined in S100A8/A9-k5-tetON versus control mice 
(Fig. 22B). Also, in vitro S100A8 and S100A9 levels in isolated, primary S100A8/A9-k5-
tetON or control keratinocytes after DOX and/or TPA treatment remained unaltered 
(Fig. 22C). 
Short time induction of mice with DOX in drinking water for 2 to 7 days, long time induc-
tion for 12 weeks, DOX administration start at different stages of mouse development 
(birth, weaning, in the resting phase of the hair cycle) to overexpress S100A8/A9 pro-
teins stayed unsuccessful as well as additional stimulation with TPA. Additionally, iso-
lated primary S100A8-A9 k5-tetON or S100A8-A9 rosa-tetON keratinocytes did not 
show upregulation of S100A8 and S100A9 upon DOX and/or TPA addition to culture 
media compared to controls. Therefore, we were unable to test the effect of ectopic 
S100A8 and S100A9 expression in mouse skin and keratinocytes. 
In summary, transgenic mice carrying a tetO-controlled S100A8-IRES-S100A9-Myc 
knock-in allele together with a ROSA-rtTA or K5-rtTA did not show a consistent increase 
of protein levels of S100A8 and S100A9 in the epidermis upon DOX administration. Al-
though, S100A8 and S100A9 expression was inducible by DOX treatment of 
tgS100A8/A9KI/+ ROSA-rtTAT/+ mouse embryonic stem cell clones (H. Schönthaler, data 
not shown) and the transgene was properly integrated (Fig. 19A). 
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4. Discussion 
 
In my diploma thesis I made use of the Jun/AP-1 psoriasis mouse model to prove that 
the genetic deletion of S100A9 leads to a global improvement of all disease symptoms. 
These include normalization of keratinocyte differentiation and proliferation in vivo, in 
addition to diminished angiogenesis and a reduced immune response at late disease 
stages. In addition, systemic levels of pro-inflammatory cytokines in serum, as well as 
the number of skin-invading immune cells were markedly decreased (Fig. 23B). These 
Fig. 22 – Treatment with TPA does induce S100A8 and S100A9 expression to the same extend 
in the epidermis of DOX-treated control and S100A8/A9-k5-tetON mice.  
(A) Schematic representation of mouse treatment. Mice received DOX in drinking water from 7 weeks 
of age, one local TPA treatment at 10.5 weeks of age and were sacrificed and analyzed 24 or 96 
hours later. 
(B-C) Western blot of total backskin of control and S100A8/A9-k5-tetON mice (B) or primary keratino-
cytes in vitro (C) treated with DOX and TPA for S100A8 and S100A9. 
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results suggest S100A9 to be a key factor in disease progression in the Jun/AP-1 pso-
riasis mouse model, but possibly also in psoriasis. 
Epidermal keratinocytes of DKO* mice become activated upon JunB and c-Jun deletion 
and exhibit a hyperproliferative state most likely due to an extrinsic feedback loop in-
volving other cell types, causing pronounced thickening of the epidermis. Differentiation 
of keratinocytes in vivo is largely abnormal, S100A8 and S100A9 are upregulated in a 
cell autonomous manner (1) and they secrete several other pro-inflammatory factors 
and chemokines. An immune response is induced and initially granulocytes invade the 
skin, followed by other innate and adaptive immune cells. Approximately three weeks 
after disease initiation, DKO* mice exhibit a full blown skin inflammation with dermal 
innate immune cell infiltrates including macrophages, granulocytes and mast cells as 
well as increased Langerhans/dermal dentritic cell numbers, epidermal neutrophils and 
T lymphocytes. DKO* mice also display a pronounced inflammation at the molecular 
level by elevated expression of inflammatory factors including S100A8 and S100A9 (1) 
and psoriasis associated genes as well as a systemic pathologic state with notably ele-
vated serum cytokine/chemokine levels (Fig. 23A). Overall, our detailed analysis further 
supports the disease developed in the Jun/AP-1 psoriasis mouse model as being highly 
reminiscent of psoriasis. 
Interestingly, activation of keratinocytes by JunB and c-Jun deletion appears to be inde-
pendent of S100A9. This is indicated by comparable numbers of MHCII-positive cells in 
the skin of DKO* and TKO* mice at early time points of disease initiation as well as a 
highly similar cytokine/chemokine secretion profile of deleted DKO* and TKO* keratino-
cytes in vitro. However, upregulation of LIF and RANTES in DKO* keratinocytes (pre-
viously described for human psoriatic leshions ((96) and (58)) appears impaired in TKO* 
keratinocytes in a cell autonomous, S100A9-dependent manner. RANTES is a known 
chemoattractant and activating factor for blood monocytes, T lymphocytes as well as 
granulocytes ((97), (98), (99) and (100)). Hence, S100A9 might not only exhibit a che-
motactic, pro-inflammatory role by itself ((26) and (24)), but also directly induce addi-
tional factors, like RANTES, in keratinocytes. 
Despite S100A9 having immunoattractant properties, the observed attenuation of al-
most all examined pathologic characteristics of the Jun/AP-1 psoriasis mouse model 
upon loss of S100A9 can hardly be explained by impaired recruitment of immune cells 
to the skin. During disease initiation, five days after tamoxifen-mediated epidermal 
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JunB/c-Jun deletion, granulocytes readily infiltrate the skin of both, DKO* and TKO* 
mice. Moreover, all tested subsets of immune cells are present in the dermis and 
epidermis of TKO* mice at later disease stages, albeit to a lesser extend when com-
pared to the Jun/AP-1 psoriasis mouse model. Cellular stress caused by the hyper-
proliferative state of keratinocytes and cutaneous immune cell infiltration in DKO* and 
TKO* mice may explain the increase of apoptotic cells in the skin. A partial 
p53-dependent apoptosis was shown to be induced by upregulated S100A9 in oeso-
phageal squamous cell carcinoma and abrogated by S100A9 knockdown (43). How-
Fig. 23 – Summary of the effects of S100A9 in the Jun/AP-1 psoriasis mouse model.  
Pronounced epidermal proliferation and inflammation in DKO* (A) and reduced pathogenesis (B) in 
TKO* mice. 
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ever, a similar mechanism in our system is unlikely, since the number of apoptotic cells 
was unaltered in the epidermis of TKO* compared to DKO* mice. We observed a signif-
icantly elevated number of apoptotic cells in the dermis of TKO* mice, which we suspect 
to be immune cells. Thus, S100A9 might prevent their death, what could also explain a 
reduced immune cell presence in the skin of the Jun/AP-1 psoriasis mouse model upon 
loss of S100A9. 
Detailed molecular characterization of an extended number of selected genes, con-
firmed that the mRNA expression pattern in the skin of DKO* compared to control mice 
is highly similar to human psoriatic skin (1). Consistent with the observed skin pheno-
type (Fig. 2B), loss of S100A9 in DKO* mice leads to a reduced inflammatory state of 
the skin on a molecular level as well. Additionally, S100A9 homozygous mutation ap-
pears to have only minor effects on the molecular phenotype of healthy skin of 
S100A9-/- versus control mice. Hence, our results suggest a promoting effect of 
S100A9 on psoriasis severity on a molecular level; therefore, S100A9 represents a 
promising candidate for regulation of psoriasis pathogenesis. 
Contribution of S100A9 to the interplay between epidermal keratinocytes and skin-
invading immune cells appears of crucial importance in psoriasis pathogenesis. Deletion 
of JunB and c-Jun in keratinocytes in mice is sufficient to induce their activation, which 
is further followed by an immune response and causes a psoriasis-like phenotype in 
vivo (1). In contrast, in vitro deleted DKO* keratinocytes are not hyperproliferative and 
DKO* and TKO* keratinocytes appear surprisingly similar. Also, immune cell infiltration 
into the skin of DKO* and TKO* mice at initial stages of disease development (5 days 
after the last tamoxifen injection) is indistinguishable. However, it remains to be shown 
in which cell type in the network of skin inflammation – keratinocytes, several immune 
cells or certain subsets – does S100A9 play its crucial role. In vitro systems of S100A9 
sufficient or deficient cell types or co-cultures of keratinocytes and immune cells provide 
only limited potential, because disease progression and a systemic contribution are not 
reproducible. Bone marrow transplantations of DKO* mice receiving TKO* bone marrow 
and vice versa is an experimental approach to address this question. 
Due to the strong upregulation of S100A8 and S100A9 in human psoriatic skin and in 
the Jun/AP-1 psoriasis mouse model, we aimed to test whether overexpression of both 
proteins is sufficient to reproduce an inflammatory state in mouse skin. Unfortunately, 
total S100A8 and S100A9 mRNA and protein levels are not upregulated in the epider-
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mis of mice carrying an inducible Tet-ON system-controlled transgene for S100A8 and 
S100A9 (tgS100A8/A9) upon DOX application. This observation was rather surprising, 
since proper integration of the tgS100A8/A9 construct in mouse ES cells 
(H. Schönthaler and G. Beranger, data not shown) and transgenic mice (Fig. 19A) was 
confirmed by Southern blot. DOX treatment induced ROSA rtTA-driven upregulation of 
S100A8 and S100A9 mRNA in tgS100A8/A9 mouse ES cells (H. Schönthaler, data not 
shown) and protein levels in 293 fibroblasts transfected with the same construct 
(J. Nehmet and P. Angel, data not shown). Moreover, we detected mRNA transcribed 
from the S100A8/A9 transgene in the epidermis of DOX-induced S100A8/A9-rosa-
tetON and S100A8/A9-k5-tetON mice and in in vitro cultured keratinocytes, but not in 
untreated or control mice and cells. Thus, total S100A8 and S100A9 mRNA levels might 
be tightly controlled by microRNAs or other cellular mechanisms in keratinocytes with-
out an inflammatory stimulus. Additional TPA-mediated stimulation of S100A8 and 
S100A9 expression did not result in increased mRNA/protein levels in DOX-induced 
S100A8/A9-rosa-tetON and S100A8/A9-k5-tetON mice and keratinocytes compared to 
controls. TgS100A8/A9 mRNA could to be unstable and may degrade, have a negative 
effect on endogenous S100A8 and S100A9 mRNA transcription/stability or Tet-ON sys-
tem-mediated expression of tgS100A8/A9 might not be too inefficient in keratinocytes. 
Therefore, I was unable to draw any conclusions from these experiments.  
Nevertheless, S100A9 loss of function studies in an inflammatory background revealed 
S100A8 and S100A9 proteins as potent mediators of skin inflammation and psoriasis. 
S100A9 deficiency leads to remarkably diminished disease pathogenesis in the 
Jun/AP-1 psoriasis mouse model (H. Schönthaler) on a macroscopic, histological and 
molecular level. Thus, S100A8/A9 proteins might represent promising targets for future 
psoriasis treatment with potentially low side effects. Epidermal expression of both pro-
teins is relatively low under steady-state conditions (38) and S100A9 loss in mice ap-
pears not to affect healthy skin, as S100A9-/- mice show no apparent skin phenotype. 
Polyclonal antibodies have been successfully used to block S100A8 and S100A9 in 
mice ((101), (102) and (103)). Testing the effect of systemic or topical application of 
neutralizing antibodies against S100A8 and/or S100A9 on disease initiation and pro-
gression in psoriasis mouse models represents a suitable approach for development of 
prospective therapies. 
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5. Materials and Methods 
 
Mouse strains and treatment of mice (H. Schönthaler) 
S100A9 loss of function approach: Mice carrying a disrupted allele of S100A9 (32), 
loxP-site flanked JunB and c-Jun alleles as well as the tamoxifen-inducible Keratin5-
CreERT transgene (1) and their littermate controls were used in this study. Eight-week 
old mice were injected intraperitoneally with 1 mg tamoxifen (Sigma) dissolved in 100µl 
Sunflower seed oil per day for 5 consecutive days to trigger Jun protein deletion and 
analyzed either 5 days (flow cytometry analysis) or around 2 weeks after the last tamox-
ifen injection. 
S100A8/A9 gain of function approach: Mice with a tet-operator controlled S100A8-
IRES-S100A9-Myc transgene (H. Schönthaler in collaboration with P. Angel, DKFZ Hei-
delberg, G.Beranger and L.Bakiri) as well as ROSA-rtTA or Keratin5-rtTA and littermate 
controls were given 0.5 gram per liter doxycycline in drinking water for the indicated 
time period before sacrifice. TPA experiment: Transgenic and control mice at 7 weeks 
of age were induced with doxycycline for 3.5 weeks followed by one-time application of 
100μl of 10-4M TPA in acetone on the freshly shaved, unwounded backskin. Analysis 
was done 24 or 96 hours after TPA treatment. 
 
Keratinocyte isolation and treatment, EdU incorporation assay and Immunocytofluores-
cence 
Ear and tail skin was disinfected with Betaisodona®, epidermis and dermis separated 
by Trypsin incubation and epidermis further digested with DNAseI (Sigma). Suspen-
sions were filtered through a 70μm cell strainer and cells plated on culture dishes 
coated with Coating Matrix Kit (Invitrogen). Keratinocytes were cultured for 24 hours in 
normal MEM (minimal essential medium) supplemented with chelated FCS, Glutamine, 
Gentamycin, Penicilin as well as Stretavidin and subsequently the medium was 
changed to Keratinocyte Serum-Free Medium (Gibco). 
Adenovirus treatment: Primary keratinocytes were incubated with 600 particles per cell 
of adenovirus containing Cre recombinase (adenoCre) or GFP (adenoGFP, provided by 
J. Guinea-Viniegra) for the indicated time period (mostly for 96 hours).  
Doxycycline and TPA treatment: Doxycyline (1µg/ml) was added to culture medium for 
4 to 72 hours depending on experiment. TPA was used in a concentration 50ng/ml for 
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24 hours. Subsequently, cells were either used for EdU incorporation assay or superna-
tant was collected for another 24 hours for cytokine array/ELISA analysis and the kera-
tinocytes harvested to isolate mRNA and protein. 
EdU incorporation assay: A Click-iT™ EdU Flow Cytometry Assay Kit with Alexa Fluor 
647 (Invitrogen Molecular Probes) was used and 10 μM Click-iT EdU (5-ethynyl-2´-
deoxyuridine) added to keratinocytes for 60 minutes to 6 hours, depending on the proli-
ferative potential of the cells due to the time they were already cultured. Keratinocytes 
were harvested and processed according to manufacturers’ instructions, Click-iT EdU 
was detected by click chemistry reaction of an alkyne (EdU) and an azide (Alexa Fluor 
647 dye) catalyzed by chopper, as described in the Click-iT™ manual from Invitrogen. 
DAPI (4',6-diamidino-2-phenylindole) was used to determine DNA content and a FACS 
Canto flow cytometer (BD Pharmingen) and BD FACSDiva software for analysis of la-
beled cells. Keratinocytes which were not incubated with EdU served as negative stain-
ing controls. 
Immunocytofluorescence: Keratinocytes were plated on Coating Matrix Kit (Invitrogen) 
coated glass coverslips, incubated with adenovirus for 72 hours and fixation performed 
with 4% paraformaldehyde (PFA). Then, cells were treated with Glycine, permeabilized 
with ice-cold Methanol and unspecific background staining blocked by the blocking 
agent of the Mouse on Mouse kit (Vector Labs). Incubation with primary c-Jun antibody 
(mouse, BD Pharmingen) and, afterwards, with Alexa Fluor 647 coupled secondary anti-
mouse antibody (Invitrogen) was performed and nuclei stained with DAPI. Cells on co-
verslips were mounted upside down in ProLong Gold antifade reagent (Invitrogen) and 
analyzed with a Nikon fluorescence microscope. 
 
Tissue stainings, Immunohistochemistry and Immufluorescence 
After sacrifice, mouse ears and/or backskin and spleen were collected and embedded in 
paraffin and/or frozen in optimal cutting temperature (OCT) medium (Tissue-Tek). Tis-
sue for paraffin processing was fixed in 3.7% PFA in 1x phosphate buffered saline 
(PBS) on 4°C overnight. Tissue dehydration was performed from ethanol, xylene to pa-
raffin in a step-wise process using a tissue processor. Subsequently, 5µm sections 
were cut with a microtome, dried at 50°C overnight and step-wise re-hydrated with xy-
lene and ethanol according to standard procedures before staining. Cut tissue sections 
were incubated with Haematoxylin (5-10 minutes) and Eosin (1-5 minutes; H&E) stain or 
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with Toluidine Blue O solution (Sigma, 3 minutes), dehydrated and mounted with a xy-
lene-based medium. TUNEL-labelling of apoptotic cells on paraffin sections employed 
the In Situ Cell Death Detection Kit (Roche) after Proteinase K-mediated antigen re-
trieval. Cell nuclei were subsequently stained with DAPI (4',6-diamidino-2-phenylindole). 
Immunohistochemistry (IHC): Antigen retrieval of tissue sections cut from paraffin 
blocks was performed by heating to 121°C for 10-20 minutes in citrate buffer by a pres-
sure cooker. Hydrogen peroxidase (3%, 5min) and 10% goat serum/1xPBS were used 
as peroxidase and protein block, respectively. The blocking agent of the Mouse on 
Mouse kit (Vector Labs) was employed before incubation with primary antibodies raised 
in mouse. Primary antibody was diluted in 10% goat serum/1xPBS and applied to the 
tissue for 2 hours at 37°C or overnight at 4°C. Secondary anti-mouse, anti-goat and an-
ti-rabbit antibodies in combination with streptavidin peroxidase and the substrate-
chromogen solution of the LSAB+ (Labeled Streptavidin Biotin) System-HRP kit (Dako) 
were used for immunohistochemical labeling according to manufacturers’ instructions. 
Visualization of cell nuclei was performed with haematoxylin. IHC on mouse ears was 
performed for Keratin5, Keratin6, Keratin10, Loricrin (all rabbit, Covance Research), 
Ki67 (rat, Dako), phospho-Histone H3 Serine 10 (rabbit, Upstate Technology), Gr.1 (rat, 
BD Pharmingen), F4/80 (rat, Santa Cruz), CD3e (goat, Santa Cruz), S100A4 (rabbit, 
Abcam) and phospho-STAT3 (rabbit, Cell Signaling). Analysis employed a Zeiss light 
microscope and respective software. 
Immunofluorescence (IF): Processing of paraffin sections for IF was performed as de-
scribed above, without peroxidase blocking. Frozen sections of 5µm were cut using a 
cryostat, fixed in 4% PFA/1xPBS (10 minutes) and treated with a protein block solution 
(bovine serum albumin, gelatine, TritonX, goat and donkey serum in 1xPBS) for one 
hour. Subsequently, tissue was incubated with primary antibodies diluted in protein 
block solution for 2 hours at 37°C or overnight at 4°C. Alexa Fluor 488 or Alexa Fluor 
647 coupled secondary antibodies (mouse, rat or rabbit, Invitrogen) were used for de-
tection of Keratin15 (mouse, Neomarker Antibodies), CD31 (rabbit, Abcam), LYVE-1 
(rabbit, Abcam), MECA32 (rat, BD Pharmingen), CD4 (rat, BD Pharmingen), CD8 (rat, 
Chemicon) and MPO (rabbit, Dako). No secondary antibody was necessary for visuali-
zation of PE-coupled MHCII (rat, BD Pharmingen) and Alexa Fluor 488-coupled Lange-
rin (rat, Dentritics) reactive product. DAPI was utilized to label nuclei, ProLong Gold an-
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tifade reagent (Invitrogen) for mounting of immunofluorescence stainings and a Nikon 
fluorescence microscope for analysis. 
Quantification of labeled cells by IHC or IF on 6 randomly taken images per mouse (10x 
or 20x magnification, as indicated) was done manually, supported by the ImageJ soft-
ware. 
 
Western blotting and quantification 
Skin was incubated swimming on 0.8% Trypsin without EDTA in 1xPBS for 45min at 
37°C to separate dermis and epidermis. RIPA buffer with added phosphate inhibitor was 
used to isolate total protein form spleen, total skin, epidermis, dermis or keratinocytes 
from in vitro cultures. Proteins were separated on 10-15% polyacrylamid gels, blotted on 
nitrocellulose membranes and blocked for 30 min in 5% milk powder in 1xPBS/0.1% 
Tween20. Primary antibodies against S100A8, S100A9 (both goat, R&D), p53, phos-
pho-p38 MAPK (both rabbit, Cell Signaling), JunB (rabbit, Santa Cruz), c-Jun (mouse, 
BD Pharmingen) or β-actin (mouse, Sigma) were used. Detection was done with Amer-
sham ECL Plus™-HRP linked secondary antibodies and western blotting detection rea-
gents according to manufacturer’s instructions on light-sensitive films. Protein band in-
tensity was quantified with Quantity One 4.6.5 software. Control was set to one and rel-
ative values are shown. 
 
Quantitative real-time PCR 
TRIzol (Invitrogen) was used for total RNA isolation from tail epidermis after Trypsin-
mediated epidermis/dermis separation according to the manufacturer’s protocol. cDNA 
was synthesized following the instructions with the Ready-To-GoTM You-Prime-It First-
Strand-Beads (GE Healthcare) and random primers (Invitrogen). Real-time PCR reac-
tions were performed in the presence of SYBR green with 5-PRIME Taq DNA Polyme-
rase and respective reagents with the Mastercycler® ep-realplex (Eppendorf). The Ct 
(cycle threshold)-value was taken at the narrow range of PCR cycles were PCR product 
is doubled per cycle and melting curve for every PCR reaction and corresponding prod-
uct was analyzed. Optimized primers for target genes have been designed using the 
Primer-BLAST software and quantification of PCR products employed the realplex anal-
ysis software and the 2-ΔΔCT analysis method. All data were normalized based on the 
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mRNA expression levels of β-actin of the sample. Control was set to one and relative 
values or fold change are shown. 
 
Cytokine array analysis and ELISA 
Blood was taken from mice at time of sacrifice by heat puncture and collected in EDTA-
containing blood collection tubes. Medium of 96 hours adenovirus-exposed primary ke-
ratinocyte cultures was changed and the supernatant collected after another 24 hours. 
Solid components of blood and 24h-conditioned medium were removed by centrifuga-
tion to yield serum and clean keratinocyte supernatant, respectively. 
Cytokine array analysis employed the Milliplex MAP Mouse Cytokine/Chemokine Panel 
I, II and III, was performed according to manufacturers’ instructions and evaluated using 
the Luminex 200 instrument and Luminex/Milliplex analyst software. Colorimetric ELISA 
kits for IL-1α, IL-6, MCP-1 or VEGF detection were purchased from R&D systems, uti-
lized according to the manual and resulting optical density measured. 
 
Flow cytometric analysis and skin cell isolation 
Cells were isolated form total ear and tailskin by digestion with Liberase (Roche) and 
DNAse I (Sigma) in HANKS buffer (one hour at 37°C) five days after five daily tamoxifen 
injections (Fig. 9A). Cells were filtered and protein blocking done with 10%FBS/1xPBS 
(30 minutes on 4°C) as well as with Fc Block antibody anti-CD16/CD32 (5 minutes on 
4°C, BD Pharmingen). Per individual staining, 106 cells were incubated (30 minutes on 
4°C) with two combinations of fluorocrome-conjugated antibodies CD3e-APC, 
CD4-PE-Cy7, CD8-FITC, B220-PE, MHCII-Alexa Fluor 700 as well as 
CD11b-PERCP-Cy5.5, Gr.1-PE-Cy7, CD11c-PE  and MHCII-Alexa Fluor 700 (all from 
BD Pharmingen, except MHCII from eBioscience) diluted in 1%BSA/1xPBS. Stainings 
were analyzed with a FACS Canto flow cytometer (BD Pharmingen), BD FACSDiva and 
FlowJo software. Every analysis was gated on single and alive cells, identified by for-
ward and side scatter (FSC and SSC) as well as DAPI-labeling of cell nuclei, except 
Fig. 9O was gated on alive, single and CD3+ cells. Positively labeled cells were deter-
mined by comparison with single antibody-stainings and staining-panel combinations 
missing one antibody. 
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Southern blot 
10µg of genomic tail DNA was digested with SpeI enzyme (Roche), separated on a 1% 
agarose gel, transferred to a genescreen membrane and cross-linked with UV light. Hy-
bridisation was done with a 3’ probe as described in (95) labeled with the Amersham 
Rediprime™ II DNA Labeling System (GE Healthcare) according to manufacturers’ in-
structions and detection performed with autoradiography films (GE Healthcare). 
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7.2. Abstract in German language / Deutsche Zusammenfassung 
 
Das Hauptaugenmerk meiner Diplomarbeit lag auf der Untersuchung der Relevanz von 
S100A8- und S100A9-Proteinen bei Entstehung und Verlauf von entzündlichen Haut-
krankheiten, im Besonderen Psoriasis (Schuppenflechte). Beide Proteine sind in der 
Haut von Psoriasis-Patienten und der Haut des Jun/AP-1-Mausmodels für Psoriasis - 
hervorgerufen durch die induzierbare, epidermale Deletion der zwei AP-1-Proteine  
JunB und c-Jun (JunBΔep* c-JunΔep*- oder DKO*-Mäuse, (1)) - deutlich überexprimiert. 
Die Induktion von S100A8 und S100A9 in Mäusen wurde bereits vor dem Auftreten von 
Krankheitssymptomen festgestellt (1). Daher stellt die Analyse der psoriasis-ähnlichen 
Krankheit bei JunBΔep* c-JunΔep*-Mäusen eine vielversprechende Möglichkeit zur Unter-
suchung der Funktion von S100A8 und S100A9 dar. Bemerkenswerterweise reduziert 
S100A9-Defizienz den Schweregrad des inflammatorischen Phänotyps des Jun/AP-1-
Mausmodels wesentlich (H. Schönthaler, unpublizierte Beobachtung). 
Bei den zwei Zelltypen, die an der Entstehung von Hautentzündungen hauptsächlich 
beteiligt sind, handelt es sich um epidermale Keratinozyten und eine Vielzahl an ver-
schiedenen Immunzellen. Die Haut des Jun/AP-1-Mausmodels zeigt sowohl beträcht-
liche epidermale Verdickung bedingt durch Hyperproliferation der Keratinozyten als 
auch ausgeprägte Infiltrierung von Immunzellen in die Dermis und Epidermis (1). Um 
herauszufinden, ob dies durch die Deletion von JunB und c-Jun auf zellautonome Wei-
se hervorgerufen wird, wurde Apoptose und Proliferation von Keratinozyten der DKO*-
Mäuse in vivo und in vitro erforscht. Wir verglichen die Ergebnisse mit JunBΔep* 
c-JunΔep* S100A9-/- (TKO*)-Mäusen zur Feststellung des Effekts einer S100A9-
Defizienz. Des Weiteren führten wir eine histologische und molekulare Charakterisie-
rung der Haut dieser Mäuse durch und analysierten die Zusammensetzung des kutanen 
Immunzell-Infiltrates von DKO*- und TKO*-Mäusen in unterschiedlichen Krankheitssta-
dien. Untersucht wurden die Zytokin-Produktion in der Dermis und Epidermis, der sys-
temische Zytokin-Gehalt im Serum sowie die Zytokin-Sekretion von kultivierten Kerati-
nozyten des Jun/AP-1 Psoriasis-Mausmodels und der TKO*-Mäuse. Dies diente zur 
Feststellung der Funktion von S100A9 im Zusammenwirken von Keratinozyten und Im-
munzellen im Verlauf von Hautentzündungen und zur Identifizierung von S100A9-
abhängigen Mediatoren dieses zellulären Netzwerks. 
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Wir vermuteten außerdem, dass Überexpression von S100A8 und S100A9 per se einen 
inflammatorischen Haut-Phänotyp hervorrufen könnte und analysierten Mäuse, welche 
ein Tet-ON-systemkontrolliertes Transgen für S100A8 und S100A9 tragen. Unglückli-
cherweise konnten wir nach Induktion der Expression des S100A8/A9 Transgenes 
durch zwei verschiedene Transaktivator-Linien keine konsistente Erhöhung der 
S100A8- oder S100A9-Proteinwerte in der Epidermis der Mäuse feststellen. 
 
S100A9 scheint entzündliche, psoriasis-ähnliche Symptome in vielfältiger Weise zu in-
duzieren. Hautarchitektur, Angiogenese und Expression von entscheidenden entzün-
dungsassoziierten Genen werden großteils durch S100A9-Defizienz des Jun/AP-1 Pso-
riasis-Mausmodels normalisiert. Darüber hinaus zeigen TKO*-Mäuse verminderte der-
male und epidermale Immunzell-Infiltrierung, reduzierte epidermale Proliferation und 
niedrigere Werte an inflammatorischen Zytokinen im Serum im Vergleich zu DKO*-
Mäusen. Obwohl S100A8 und S100A9 in Keratinozyten infolge von JunB- und c-Jun-
Deletion in vitro hochreguliert werden (1), hat dies keine zellautonome Auswirkung auf 
deren Proliferation. S100A9 hat auch keinen ausgeprägten Effekt auf die Sekretion von 
inflammatorischen Zytokinen durch Keratinozyten in vitro, nachdem sich die gemesse-
nen Werte in den Kulturmedien von DKO*- und TKO*-Keratinozyten kaum unterschei-
den. Daher scheint S100A9 eine komplexe Rolle im Zusammenwirken von Keratinozy-
ten und Immunzellen zu spielen und außerdem eine Induzierung und Amplifikation des 
Schweregrades von Psoriasis und Hautentzündungsreaktionen zu bewirken. 
 
 
